Document And Entity Information
Document And Entity Information - shares | 3 Months Ended | |
Mar. 31, 2020 | Apr. 30, 2020 | |
Document Information [Line Items] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Period End Date | Mar. 31, 2020 | |
Document Fiscal Year Focus | 2020 | |
Document Fiscal Period Focus | Q1 | |
Entity Registrant Name | Arlington Asset Investment Corp. | |
Entity Central Index Key | 0001209028 | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Accelerated Filer | |
Entity Emerging Growth Company | false | |
Entity Small Business | true | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Shell Company | false | |
Entity File Number | 001-34374 | |
Entity Incorporation, State or Country Code | VA | |
Entity Tax Identification Number | 54-1873198 | |
Entity Common Stock, Shares Outstanding | 36,815,761 | |
Entity Address, Address Line One | 6862 Elm Street | |
Entity Address, Address Line Two | Suite 320 | |
Entity Address, City or Town | McLean | |
Entity Address, State or Province | VA | |
Entity Address, Postal Zip Code | 22101 | |
City Area Code | 703 | |
Local Phone Number | 373-0200 | |
Document Quarterly Report | true | |
Document Transition Report | false | |
Class A Common | ||
Document Information [Line Items] | ||
Title of 12(b) Security | Class A Common Stock | |
Security Exchange Name | NYSE | |
Trading Symbol | AI | |
7.00% Series B Cumulative Perpetual Redeemable Preferred Stock | ||
Document Information [Line Items] | ||
Title of 12(b) Security | 7.00% Series B Cumulative Perpetual Redeemable Preferred Stock | |
Security Exchange Name | NYSE | |
Trading Symbol | AI PrB | |
8.250% Series C Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock | ||
Document Information [Line Items] | ||
Title of 12(b) Security | 8.250% Series C Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock | |
Security Exchange Name | NYSE | |
Trading Symbol | AI PrC | |
6.625% Senior Notes due 2023 | ||
Document Information [Line Items] | ||
Title of 12(b) Security | 6.625% Senior Notes due 2023 | |
Security Exchange Name | NYSE | |
Trading Symbol | AIW | |
6.75% Senior Notes due 2025 | ||
Document Information [Line Items] | ||
Title of 12(b) Security | 6.75% Senior Notes due 2025 | |
Security Exchange Name | NYSE | |
Trading Symbol | AIC |
CONSOLIDATED BALANCE SHEETS
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
ASSETS | ||
Cash and cash equivalents | $ 89,376 | $ 19,636 |
Interest receivable | 6,126 | 10,663 |
Sold securities receivable | 1,479,396 | 71,199 |
Mortgage loans, at fair value | 44,614 | 45,000 |
Derivative assets, at fair value | 16,963 | 1,417 |
Deposits | 33,008 | 37,123 |
Other assets | 11,200 | 13,079 |
Total assets | 2,358,307 | 4,000,114 |
Liabilities: | ||
Repurchase agreements | 2,036,466 | 3,581,237 |
Interest payable | 1,199 | 4,666 |
Accrued compensation and benefits | 832 | 3,626 |
Dividend payable | 37 | 8,494 |
Derivative liabilities, at fair value | 11,828 | 8 |
Other liabilities | 753 | 507 |
Long-term unsecured debt | 74,383 | 74,328 |
Total liabilities | 2,125,498 | 3,672,866 |
Commitments and contingencies | ||
Stockholders’ Equity: | ||
Additional paid-in capital | 2,049,741 | 2,049,292 |
Accumulated deficit | (1,854,498) | (1,759,626) |
Total stockholders’ equity | 232,809 | 327,248 |
Total liabilities and stockholders’ equity | 2,358,307 | 4,000,114 |
Agency MBS | ||
ASSETS | ||
Mortgage-backed securities, at fair value | 645,001 | 3,768,496 |
Liabilities: | ||
Repurchase agreements | 1,977,095 | 3,560,139 |
Non-Agency MBS | ||
ASSETS | ||
Mortgage-backed securities, at fair value | 32,623 | 33,501 |
Liabilities: | ||
Repurchase agreements | 27,871 | 21,098 |
Series B Preferred Stock | ||
Stockholders’ Equity: | ||
Preferred stock | 8,264 | 8,270 |
Series C Preferred Stock | ||
Stockholders’ Equity: | ||
Preferred stock | 28,934 | 28,944 |
Common Class A | ||
Stockholders’ Equity: | ||
Common stock | $ 368 | $ 368 |
CONSOLIDATED BALANCE SHEETS (Pa
CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Series B Preferred Stock | ||
Preferred stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Preferred stock, issued (in shares) | 354,039 | 354,039 |
Preferred stock, outstanding (in shares) | 354,039 | 354,039 |
Preferred stock, liquidation preference | $ 8,851 | $ 8,851 |
Series C Preferred Stock | ||
Preferred stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Preferred stock, issued (in shares) | 1,200,000 | 1,200,000 |
Preferred stock, outstanding (in shares) | 1,200,000 | 1,200,000 |
Preferred stock, liquidation preference | $ 30,000 | $ 30,000 |
Common Class A | ||
Common stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Common stock, shares authorized (in shares) | 450,000,000 | 450,000,000 |
Common stock, shares issued (in shares) | 36,815,761 | 36,755,387 |
Common stock, shares outstanding (in shares) | 36,815,761 | 36,755,387 |
CONSOLIDATED STATEMENTS OF COMP
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Interest income | ||
Mortgage loans | $ 711 | |
Other | 143 | $ 261 |
Total interest income | 24,973 | 33,832 |
Interest expense | ||
Total interest expense | 15,832 | 25,915 |
Net interest income | 9,141 | 7,917 |
Investment advisory fee income | 250 | |
Investment (loss) gain, net | ||
Gain on trading investments, net | 3,094 | 69,168 |
Loss from derivative instruments, net | (102,600) | (55,205) |
Other, net | (562) | (160) |
Total investment (loss) gain, net | (100,068) | 13,803 |
General and administrative expenses | ||
Compensation and benefits | 1,858 | 3,116 |
Other general and administrative expenses | 1,385 | 1,260 |
Total general and administrative expenses | 3,243 | 4,376 |
Net (loss) income | (94,170) | 17,594 |
Dividend on preferred stock | (774) | (278) |
Net (loss) income (attributable) available to common stock | $ (94,944) | $ 17,316 |
Basic (loss) earnings per common share | $ (2.59) | $ 0.52 |
Diluted (loss) earnings per common share | $ (2.59) | $ 0.52 |
Weighted-average common shares outstanding (in thousands) | ||
Basic | 36,711 | 33,053 |
Diluted | 36,711 | 33,139 |
Secured Debt | ||
Interest expense | ||
Short-term debt | $ 14,592 | $ 24,643 |
Unsecured Debt | ||
Interest expense | ||
Long-term debt | 1,240 | 1,272 |
Agency MBS | ||
Interest income | ||
Mortgage-backed securities | 23,388 | 33,570 |
Non-Agency MBS | ||
Interest income | ||
Mortgage-backed securities | 731 | 1 |
Investment (loss) gain, net | ||
Gain on trading investments, net | $ (20,038) | $ 3 |
CONSOLIDATED STATEMENTS OF CHAN
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Unaudited) - USD ($) $ in Thousands | Total | Common Class A | Preferred Stock | Preferred StockSeries B Preferred Stock | Preferred StockSeries C Preferred Stock | Common StockCommon Class A | Additional Paid-in Capital | Accumulated Deficit |
Balances at Dec. 31, 2018 | $ 274,444 | $ 8,245 | $ 305 | $ 1,997,876 | $ (1,731,982) | |||
Balances (in shares) at Dec. 31, 2018 | 350,595 | 30,497,998 | ||||||
Net income (loss) | 17,594 | 17,594 | ||||||
Issuance of stock | $ 48,810 | $ 28,925 | $ 45 | $ 28,880 | $ 60 | 48,750 | ||
Issuance of stock (in shares) | 2,035 | 1,200,000 | 6,000,000 | |||||
Issuance of Class A common stock under stock-based compensation plans | $ 1 | (1) | ||||||
Issuance of Class A common stock under stock-based compensation plans (in shares) | 74,619 | |||||||
Stock-based compensation | 773 | 773 | ||||||
Dividends declared | (14,135) | (14,135) | ||||||
Balances at Mar. 31, 2019 | 356,411 | $ 8,290 | $ 28,880 | $ 366 | 2,047,398 | (1,728,523) | ||
Balances (in shares) at Mar. 31, 2019 | 352,630 | 1,200,000 | 36,572,617 | |||||
Balances at Dec. 31, 2018 | 274,444 | $ 8,245 | $ 305 | 1,997,876 | (1,731,982) | |||
Balances (in shares) at Dec. 31, 2018 | 350,595 | 30,497,998 | ||||||
Balances at Dec. 31, 2019 | 327,248 | $ 8,270 | $ 28,944 | $ 368 | 2,049,292 | (1,759,626) | ||
Balances (in shares) at Dec. 31, 2019 | 354,039 | 1,200,000 | 36,755,387 | |||||
Net income (loss) | (94,170) | (94,170) | ||||||
Issuance of stock | $ (6) | $ (16) | $ (6) | $ (10) | (6) | |||
Issuance of Class A common stock under stock-based compensation plans | 62 | 62 | ||||||
Issuance of Class A common stock under stock-based compensation plans (in shares) | 60,374 | |||||||
Stock-based compensation | 393 | 393 | ||||||
Dividends declared | (702) | (702) | ||||||
Balances at Mar. 31, 2020 | $ 232,809 | $ 8,264 | $ 28,934 | $ 368 | $ 2,049,741 | $ (1,854,498) | ||
Balances (in shares) at Mar. 31, 2020 | 354,039 | 1,200,000 | 36,815,761 |
CONSOLIDATED STATEMENTS OF CASH
CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Cash flows from operating activities: | ||
Net (loss) income | $ (94,170) | $ 17,594 |
Adjustments to reconcile net (loss) income to net cash provided by operating activities | ||
Investment loss (gain), net | 100,068 | (13,803) |
Net premium amortization on mortgage-backed securities | 4,587 | 5,943 |
Other | 521 | 833 |
Changes in operating assets | ||
Interest receivable | 4,536 | (779) |
Other assets | (86) | (493) |
Changes in operating liabilities | ||
Interest payable and other liabilities | (3,282) | 689 |
Accrued compensation and benefits | (2,794) | (2,312) |
Net cash provided by operating activities | 9,380 | 7,672 |
Cash flows from investing activities: | ||
Proceeds from sales of agency mortgage-backed securities | 1,762,433 | 461,558 |
Proceeds from sales of non-agency mortgage-backed securities | 30,054 | |
Receipt of principal payments on agency mortgage-backed securities | 121,715 | 94,067 |
Receipt of principal payments on non-agency mortgage-backed securities | 1 | |
Payments for derivatives and deposits, net | (100,818) | (67,803) |
Other | 71 | |
Net cash provided by (used in) investing activities | 1,614,251 | (305,385) |
Cash flows from financing activities: | ||
(Repayments of) proceeds from repurchase agreements, net | (1,544,771) | 242,498 |
(Payments for) proceeds from issuance of common stock | (6) | 48,810 |
(Payments for) proceeds from issuance of preferred stock | (16) | 28,925 |
Dividends paid | (9,098) | (11,686) |
Net cash (used in) provided by financing activities | (1,553,891) | 308,547 |
Net increase in cash and cash equivalents | 69,740 | 10,834 |
Cash and cash equivalents, beginning of period | 19,636 | 26,713 |
Cash and cash equivalents, end of period | 89,376 | 37,547 |
Supplemental cash flow information: | ||
Cash payments for interest | 19,243 | 25,442 |
Non-Agency MBS | ||
Cash flows from investing activities: | ||
Purchases of mortgage-backed securities | (49,353) | |
Agency MBS | ||
Cash flows from investing activities: | ||
Purchases of mortgage-backed securities | $ (149,781) | $ (793,278) |
Organization and Basis of Prese
Organization and Basis of Presentation | 3 Months Ended |
Mar. 31, 2020 | |
Organization Consolidation And Presentation Of Financial Statements [Abstract] | |
Organization and Basis of Presentation | Note 1. Organization and Basis of Presentation Arlington Asset Investment Corp. (“Arlington Asset”) and its consolidated subsidiaries (unless the context otherwise provides, collectively, the “Company”) is an investment firm that focuses on acquiring and holding a levered portfolio of mortgage investments generally consisting of agency mortgage-backed securities (“MBS”) and mortgage credit investments. The Company’s agency MBS include residential mortgage pass-through certificates for which the principal and interest payments are guaranteed by either a U.S. government sponsored enterprise (“GSE”), such as the Federal National Mortgage Association (“Fannie Mae”) and the Federal Home Loan Mortgage Corporation (“Freddie Mac”), or by a U.S. government agency, such as the Government National Mortgage Association (“Ginnie Mae”). The Company’s mortgage credit investments may include investments in mortgage loans secured by either residential or commercial real property or MBS collateralized by such mortgage loans, which the Company refers to as non-agency MBS. The principal and interest of the Company’s mortgage credit investments are not guaranteed by a GSE or a U.S. government agency. Arlington Asset is a Virginia corporation that is internally managed and does not have an external investment advisor. We intend to elect to be taxed as a real estate investment trust (“REIT”) under the Internal Revenue Code of 1986, as amended (the “Internal Revenue Code”) upon filing our tax return for our taxable year ended December 31, 2019. As a REIT, the Company will be required to distribute annually 90% of its REIT taxable income (subject to certain adjustments). So long as the Company continues to qualify as a REIT, it will generally not be subject to U.S. Federal or state corporate income taxes on its taxable income that it distributes to its shareholders on a timely basis. At present, it is the Company’s intention to distribute 100% of its taxable income, although the Company will not be required to do so. The Company intends to make distributions of its taxable income within the time limits prescribed by the Internal Revenue Code, which may extend into the subsequent taxable year The unaudited interim consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and pursuant to the requirements for reporting on Form 10-Q and Article 10 of Regulation S-X. The Company’s unaudited interim consolidated financial statements and notes thereto should be read in conjunction with the Company’s audited annual consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019. The Company’s consolidated financial statements include the accounts of Arlington Asset and all other entities in which the Company has a controlling financial interest. All intercompany accounts and transactions have been eliminated in consolidation. The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect amounts reported in the consolidated financial statements. Although the Company bases these estimates and assumptions on historical experience and all other reasonably available information that the Company believes to be relevant under the circumstances, such estimates frequently require management to exercise significant subjective judgment about matters that are inherently uncertain. Actual results may differ from these estimates materially. Certain amounts in the consolidated financial statements and notes for prior periods have been reclassified to conform to the current year’s presentation. These reclassifications had no impact on the previously reported net income, total assets or total liabilities. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 3 Months Ended |
Mar. 31, 2020 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | Note 2. Summary of Significant Accounting Policies Cash Equivalents Cash equivalents include demand deposits with banks, money market accounts and highly liquid investments with original maturities of three months or less. As of March 31, 2020 and December 31, 2019, approximately 99% and 97%, respectively, of the Company’s cash equivalents were invested in money market funds that invest primarily in U.S. Treasuries and other securities backed by the U.S. government. Investment Security Purchases and Sales Purchases and sales of investment securities are recorded on the settlement date of the transfer unless the trade qualifies as a “regular-way” trade and the associated commitment qualifies for an exemption from the accounting guidance applicable to derivative instruments. A regular-way trade is an investment security purchase or sale transaction that is expected to settle within the period of time following the trade date that is prevalent or traditional for that specific type of security. Any amounts payable or receivable for unsettled security trades are recorded as “sold securities receivable” or “purchased securities payable” in the consolidated balance sheets. Interest Income Recognition for Investments in Agency MBS The Company recognizes interest income for its investments in agency MBS by applying the “interest method” permitted by GAAP, whereby purchase premiums and discounts are amortized and accreted, respectively, as an adjustment to contractual interest income accrued at each security’s stated coupon rate. The interest method is applied at the individual security level based upon each security’s effective interest rate. The Company calculates each security’s effective interest rate at the time of purchase by solving for the discount rate that equates the present value of that security's remaining contractual cash flows (assuming no principal prepayments) to its purchase price. Because each security’s effective interest rate does not reflect an estimate of future prepayments, the Company refers to this manner of applying the interest method as the “contractual effective interest method.” When applying the contractual effective interest method to its investments in agency MBS, as principal prepayments occur, a proportional amount of the unamortized premium or discount is recognized in interest income such that the contractual effective interest rate on the remaining security balance is unaffected. Interest Income Recognition for Investments in Non-Agency MBS The Company recognizes interest income for its investments in non-agency MBS by applying the prospective level-yield methodology required by GAAP for securitized financial assets that are either not of high credit quality at the time of acquisition or can be contractually prepaid or otherwise settled in such a way that the Company would not recover substantially all of its recorded investment. The amount of periodic interest income recognized is determined by applying the security’s effective interest rate to its amortized cost basis (or “reference amount”). At the time of acquisition, the security’s effective interest rate is calculated by solving for the single discount rate that equates the present value of the Company’s best estimate of the amount and timing of the cash flows expected to be collected from the security to its purchase price. To prepare its best estimate of cash flows expected to be collected, the Company develops a number of assumptions about the future performance of the pool of mortgage loans that serve as collateral for its investment, including assumptions about the timing and amount of prepayments and credit losses. In each subsequent quarterly reporting period, the amount and timing of cash flows expected to be collected from the security are re-estimated based upon current information and events. The following table provides a description of how periodic changes in the estimate of cash flows expected to be collected affect interest income recognition prospectively for investments in non-agency MBS: Scenario: Effect on Interest Income Recognition for Investments in Non-Agency MBS: A positive change in cash flows occurs. Actual cash flows exceed prior estimates and/or a positive change occurs in the estimate of expected remaining cash flows. A revised effective interest rate is calculated and applied prospectively such that the positive change in cash flows is recognized as incremental interest income over the remaining life of the security. The amount of periodic interest income recognized over the remaining life of the security will be reduced accordingly. Specifically, if an adverse change in cash flows occurs for a security that is impaired (that is, its fair value is less than its reference amount), the reference amount to which the security’s existing effective interest rate will be prospectively applied will be reduced to the present value of cash flows expected to be collected, discounted at the security’s existing effective interest rate. If an adverse change in cash flows occurs for a security that is not impaired, the security’s effective interest rate will be reduced accordingly and applied on a prospective basis. An adverse change in cash flows occurs. Actual cash flows fall short of prior estimates and/or an adverse change occurs in the estimate of expected remaining cash flows. Other Significant Accounting Policies Certain of the Company’s other significant accounting policies are summarized in the following notes: Investments in agency MBS, subsequent measurement Note 3 Investments in non-agency MBS, subsequent measurement Investments in mortgage loans, subsequent measurement Borrowings Note 4 Note 5 Note 6 To-be-announced agency MBS transactions, including “dollar rolls” Note 7 Derivative instruments Note 7 Balance sheet offsetting Note 8 Fair value measurements Note 9 Refer to the Company’s 2019 Annual Report on Form 10-K for a complete inventory and summary of the Company’s significant accounting policies. Recent Accounting Pronouncements The following table provides a brief description of recently issued accounting pronouncements and their actual or expected effect on the Company’s consolidated financial statements: Standard Description Date of Adoption Effect on the Consolidated Financial Statements Recently Adopted Accounting Guidance ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 606) The amendments in this update require financial assets measured at amortized cost as well as available-for-sale debt securities to be measured for impairment on the basis of the net amount expected to be collected. Credit losses are to be recognized through an allowance for credit losses, which differs from the direct write-down of the amortized cost basis previously required for other-than-temporary impairments of investments in debt securities. This update also makes substantial changes to the manner in which interest income is to be recognized for financial assets acquired with a more-than-insignificant amount of credit deterioration since origination. This update does not affect the accounting for investments in debt securities that are classified as trading securities. January 1, 2020 All of the Company’s investments in debt securities are classified as trading securities. Accordingly, the adoption of ASU No. 2016-13 did not have an effect on the Company’s consolidated financial statements. Recently Issued Accounting Guidance Not Yet Adopted ASU No. 2020-04, Reference Rate Reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting The amendments in this update provide optional practical expedients and exceptions for applying GAAP to the modification of receivables, debt, or lease contracts as well as cash flow and fair value hedge accounting relationships that reference a rate, such as LIBOR, that is expected to be discontinued because of reference rate reform. The practical expedients and exceptions provided by the update are effective from March 12, 2020 through December 31, 2022. Not yet adopted. To date, the Company has not made any modifications to contracts due to reference rate reform. The Company has not elected to apply hedge accounting for financial reporting purposes. |
Investments in Agency MBS
Investments in Agency MBS | 3 Months Ended |
Mar. 31, 2020 | |
Agency MBS | |
Investments in MBS | Note 3. Investments in Agency MBS The Company has elected to classify its investments in agency MBS as trading securities. Accordingly, the Company’s investments in agency MBS are reported in the accompanying consolidated balance sheets at fair value . As of March 31, 2020 and December 31, 2019, the fair value of the Company’s investments in agency MBS was $645,001 and $3,768,496, respectively. All periodic changes in the fair value of agency MBS that are not attributed to interest income are recognized as a component of “investment gain (loss), net” in the accompanying consolidated statements of comprehensive income. The following table provides additional information about the gains and losses recognized as a component of “investment gain (loss), net” in the Company’s consolidated statements of comprehensive income for the periods indicated with respect to investments in agency MBS: Three Months Ended March 31, 2020 2019 Net gains (losses) recognized in earnings for: Agency MBS still held at period end $ 12,127 $ 62,109 Agency MBS sold during the period 11,391 7,056 Total $ 23,518 $ 69,165 The Company also invests in and finances fixed-rate agency MBS on a generic pool basis through sequential series of to-be-announced security transactions commonly referred to as “dollar rolls.” Dollar rolls are accounted for as a sequential series of derivative instruments. Refer to “Note 7. Derivative Instruments” for further information about dollar rolls. |
Investments in Non-Agency MBS
Investments in Non-Agency MBS | 3 Months Ended |
Mar. 31, 2020 | |
Non-Agency MBS | |
Investments in MBS | Note 4. Investments in Non-Agency MBS The Company has elected to classify its investments in non-agency MBS as trading securities. Accordingly, the Company’s investments in non-agency MBS are reported in the accompanying consolidated balance sheets at fair value. As of March 31, 2020 and December 31, 2019, the fair value of the Company’s investments in non-agency MBS was $32,623 and $33,501, respectively. As of March 31, 2020, the Company’s investments in non-agency MBS represent beneficial interests in mortgages secured by commercial real property (commercial MBS or “CMBS”) and residential real property (residential MBS or “RMBS”). The Company’s investments in non-agency CMBS represent beneficial interests in underlying pools of smaller balance commercial mortgage loans or a single, large balance commercial mortgage loan. Credit losses incurred on the underlying mortgage loans collateralizing the Company’s investments in non-agency CMBS are allocated on a “reverse sequential” basis. Accordingly, any credit losses realized on the underlying mortgage loans are first absorbed by the beneficial interests subordinate to the Company’s non-agency CMBS, to the extent of their respective principal balance, prior to being allocated to Company’s investments. Periodic interest accrues on each security’s outstanding principal balance at its contractual coupon rate. The Company’s non-agency RMBS investment represents a first loss position in a pool of business-purpose residential mortgage loans. The pool of underlying mortgage loans consists of fixed-rate, short-term, interest-only mortgage loans (with the full amount of principal due at maturity) made to professional real estate investors and are secured by first lien positions in non-owner occupied residential real estate. The properties that secure these mortgage loans often require construction, repair, or rehabilitation. The repayment of the mortgage loans is often largely based on the ability of the borrower to sell the mortgaged property or to convert the property for rental purposes and obtain refinancing in the form of a longer-term loan. The Company’s non-agency RMBS investment is entitled to any excess of the monthly interest payments from the underlying pool of mortgage loans (net of loan servicing and trust administrative fees) over the interest payments made to the trust’s senior note holders. Credit losses realized on the underlying pool of mortgage loans are first allocated to the Company’s non-agency RMBS, to the extent of its principal balance, prior to being allocated to the trust’s senior noteholders. All periodic changes in the fair value of non-agency MBS that are not attributed to interest income are recognized as a component of “investment gain (loss), net” in the accompanying consolidated statements of comprehensive income. The following table provides additional information about the gains and losses recognized as a component of “investment gain (loss), net” in the Company’s consolidated statements of comprehensive income for the periods indicated with respect to investments in non-agency MBS: Three Months Ended March 31, 2020 2019 Net gains (losses) recognized in earnings for: Non-agency MBS still held at period end $ (15,618 ) $ 3 Non-agency MBS sold during the period (4,420 ) — Total $ (20,038 ) $ 3 |
Investments in Mortgage Loans
Investments in Mortgage Loans | 3 Months Ended |
Mar. 31, 2020 | |
Investments Debt And Equity Securities [Abstract] | |
Investments in Mortgage Loans | Note 5. Investments in Mortgage Loans On December 31, 2019, the Company acquired a $45,000 mortgage loan secured by a first lien position in healthcare facilities. The mortgage loan bears interest at a floating note rate equal to one-month LIBOR plus 4.25% with a note rate floor of 6.25%. The maturity date of the loan is December 31, 2021 with a one-year extension available at the option of the borrower. The mortgage loan has an initial interest-only period of one year followed by principal amortization based upon a 30-year amortization schedule beginning in 2021 with the remaining principal balance due at loan maturity. As of March 31, 2020 and December 31, 2019, the fair value of the Company’s investments in mortgage loans were $44,614 and $45,000, respectively. The Company recognizes interest income on its mortgage loan investment based upon the contractual note rate of the loan. The Company has elected to account for its mortgage loan investment at fair value on a recurring basis with periodic changes in fair value recognized as a component of “investment gain (loss), net” in the accompanying consolidated statements of comprehensive income. |
Borrowings
Borrowings | 3 Months Ended |
Mar. 31, 2020 | |
Debt Disclosure [Abstract] | |
Borrowings | Note 6. Borrowings Repurchase Agreements The Company finances the purchase of mortgage investments through repurchase agreements, which are accounted for as collateralized borrowing arrangements. In a repurchase transaction, the Company sells a mortgage investment to a counterparty under a master repurchase agreement in exchange for cash and concurrently agrees to repurchase the same asset at a future date in an amount equal to the cash initially exchanged plus an agreed-upon amount of interest. Mortgage investments sold under agreements to repurchase remain on the Company’s consolidated balance sheets because the Company maintains effective control over such assets throughout the duration of the arrangement. Throughout the contractual term of a repurchase agreement, the Company recognizes a “repurchase agreement” liability on its consolidated balance sheets to reflect the obligation to repay to the counterparty the proceeds received upon the initial transfer of the mortgage investment. The difference between the proceeds received by the Company upon the initial transfer of the mortgage investment and the contractually agreed-upon repurchase price is recognized as interest expense ratably over the term of the repurchase arrangement. Amounts borrowed pursuant to repurchase agreements are equal in value to a specified percentage of the fair value of the pledged collateral. The Company retains beneficial ownership of the pledged collateral throughout the term of the repurchase agreement. The counterparty to the repurchase agreements may require that the Company pledge additional securities or cash as additional collateral to secure borrowings when the value of the collateral declines. The Company’s MBS repurchase agreement arrangements generally carry a fixed rate of interest and are short-term in nature with contract durations generally ranging from 30 to 60 days, but may be as short as one day or as long as one year. The Company’s mortgage loan repurchase agreement arrangement has a maturity date of February 9, 2021 and an interest rate that resets monthly at a rate equal to one-month LIBOR plus 2.00% with an interest rate floor of 3.00%. Under the terms of the Company’s mortgage loan repurchase agreement, the Company may request extensions of the maturity date of the agreement by up to 364 days, subject to the lender’s approval. As of March 31, 2020 and December 31, 2019, the Company had no amount at risk with a single repurchase agreement counterparty or lender greater than 10% of equity. The following table provides information regarding the Company’s outstanding repurchase agreement borrowings as of the dates indicated: March 31, 2020 December 31, 2019 Agency MBS repurchase financing: Repurchase agreements outstanding $ 1,977,095 $ 3,560,139 Agency MBS collateral, at fair value (1) 2,094,164 3,741,399 Net amount (2) 117,069 181,260 Weighted-average rate 0.92 % 2.10 % Weighted-average term to maturity 15.0 days 23.7 days Non-agency MBS repurchase financing: Repurchase agreements outstanding $ 27,871 $ 21,098 MBS collateral, at fair value (3) 41,230 30,747 Net amount (2) 13,359 9,649 Weighted-average rate 3.13 % 3.11 % Weighted-average term to maturity 5.3 days 8.1 days Mortgage loans repurchase financing: Repurchase agreements outstanding $ 31,500 $ — Mortgage loans collateral, at fair value 44,614 — Net amount (2) 13,114 — Weighted-average rate 3.00 % — Weighted-average term to maturity 315.0 days — Total mortgage investments repurchase financing: Repurchase agreements outstanding $ 2,036,466 $ 3,581,237 Mortgage investments collateral, at fair value 2,180,008 3,772,146 Net amount (2) 143,542 190,909 Weighted-average rate 0.98 % 2.11 % Weighted-average term to maturity 19.5 days 23.6 days (1) As of March 31, 2020 and December 31, 2019, includes $1,455,136 and $71,284, respectively, at sale price of unsettled agency MBS sale commitments which are included in the line item “sold securities receivable” in the accompanying consolidated balance sheets. (2) Net amount represents the value of collateral in excess of corresponding repurchase obligation. The amount of collateral at-risk is limited to the outstanding repurchase obligation and not the entire collateral balance. (3) As of March 31, 2020, includes $32,607 and $8,623 at fair value of non-agency and agency MBS collateral, respectively. As of December 31, 2019, includes $30,747 at fair value of non-agency MBS collateral. The following table provides information regarding the Company’s outstanding repurchase agreement borrowings during the three months ended March 31, 2020 and 2019: March 31, 2020 March 31, 2019 Weighted-average outstanding balance during the three months ended $ 3,162,340 $ 3,680,429 Weighted-average rate during the three months ended 1.83 % 2.68 % Long-Term Unsecured Debt As of March 31, 2020 and December 31, 2019, the Company had $74,383 and $74,328, respectively, of outstanding long-term unsecured debentures, net of unamortized debt issuance costs of $917 and $972, respectively. The Company’s long-term debentures consisted of the following as of the dates indicated: March 31, 2020 December 31, 2019 Senior Notes Due 2025 Senior Notes Due 2023 Trust Preferred Debt Senior Notes Due 2025 Senior Notes Due 2023 Trust Preferred Debt Outstanding Principal $ 35,300 $ 25,000 $ 15,000 $ 35,300 $ 25,000 $ 15,000 Annual Interest Rate 6.75 % 6.625 % LIBOR+ 2.25 - 3.00 % 6.75 % 6.625 % LIBOR+ 2.25 - 3.00 % Interest Payment Frequency Quarterly Quarterly Quarterly Quarterly Quarterly Quarterly Weighted-Average Interest Rate 6.75 % 6.625 % 4.58 % 6.75 % 6.625 % 4.74 % Maturity March 15, 2025 May 1, 2023 2033 - 2035 March 15, 2025 May 1, 2023 2033 - 2035 The Senior Notes due 2023 and the Senior Notes due 2025 are publicly traded on the New York Stock Exchange under the ticker symbols “AIW” and “AIC,” respectively. The Senior Notes due 2023, Senior Notes due 2025 and Trust Preferred Debt may be redeemed in whole or in part at any time and from time to time at the Company’s option at a redemption price equal to the principal amount plus accrued and unpaid interest. The indenture governing the Senior Notes contains certain covenants, including limitations on the Company’s ability to merge or consolidate with other entities or sell or otherwise dispose of all or substantially all of the Company’s assets. |
Derivative Instruments
Derivative Instruments | 3 Months Ended |
Mar. 31, 2020 | |
Derivative Instruments And Hedging Activities Disclosure [Abstract] | |
Derivative Instruments | Note 7. Derivative Instruments In the normal course of its operations, the Company is a party to financial instruments that are accounted for as derivative instruments. Derivative instruments are recorded at fair value as either “derivative assets” or “derivative liabilities” in the consolidated balance sheets, with all periodic changes in fair value reflected as a component of “investment gain (loss), net” in the consolidated statements of comprehensive income. Cash receipts or payments related to derivative instruments are classified as investing activities within the consolidated statements of cash flows. Types and Uses of Derivative Instruments Interest Rate Hedging Instruments The Company is party to interest rate hedging instruments that are intended to economically hedge changes, attributable to changes in benchmark interest rates, in certain MBS fair values and future interest cash flows on the Company’s short-term financing arrangements. Interest rate hedging instruments include centrally cleared interest rate swaps, exchange-traded instruments, such as U.S. Treasury note futures, Eurodollar futures, interest rate swap futures and options on futures, and non-exchange-traded instruments such as options on agency MBS. While the Company uses its interest rate hedging instruments to economically hedge a portion of its interest rate risk, it has not designated such contracts as hedging instruments for financial reporting purposes. The Company exchanges cash “variation margin” with the counterparties to its interest rate hedging instruments at least on a daily basis based upon daily changes in fair value as measured by the Chicago Mercantile Exchange (“CME”), the central clearinghouse through which those instruments are cleared. In addition, the CME requires market participants to deposit and maintain an “initial margin” amount which is determined by the CME and is generally intended to be set at a level sufficient to protect the CME from the maximum estimated single-day price movement in that market participant’s contracts . However, futures commission merchants may require “initial margin” in excess of the CME’s requirement Receivables recognized for the right to reclaim cash initial margin posted in respect of interest rate hedging instruments are included in the line item “deposits” in the accompanying consolidated balance sheets. The daily exchange of variation margin associated with a centrally cleared or exchange-traded hedging instrument is legally characterized as the daily settlement of the instrument itself, as opposed to a pledge of collateral. Accordingly, the Company accounts for the daily receipt or payment of variation margin associated with its interest rate swaps and futures as a direct reduction to the carrying value of the derivative asset or liability, respectively. The carrying amount of interest rate swaps and futures reflected in the Company’s consolidated balance sheets is equal to the unsettled fair value of such instruments; because variation margin is exchanged on a one-day lag, the unsettled fair value of such instruments generally represents the change in fair value that occurred on the last day of the reporting period. To-Be-Announced Agency MBS Transactions, Including “Dollar Rolls” In addition to interest rate hedging instruments that are used for interest rate risk management, the Company is a party to derivative instruments that economically serve as investments, such as forward commitments to purchase fixed-rate “pass-through” agency MBS on a non-specified pool basis, which are known as to-be-announced (“TBA”) securities. A TBA security is a forward commitment for the purchase or sale of a fixed-rate agency MBS at a predetermined price, face amount, issuer, coupon, and stated maturity for settlement on an agreed upon future date. The specific agency MBS that will be delivered to satisfy the TBA trade is not known at the inception of the trade. The specific agency MBS to be delivered is determined 48 hours prior to the settlement date. The Company accounts for TBA securities as derivative instruments because the Company cannot assert that it is probable at inception and throughout the term of an individual TBA commitment that its settlement will result in physical delivery of the underlying agency MBS, or the individual TBA commitment will not settle in the shortest time period possible. The Company’s agency MBS investment portfolio includes net purchase (or “net long”) positions in TBA securities, which are primarily the result of executing sequential series of “dollar roll” transactions. The Company executes dollar roll transactions as a means of investing in and financing non-specified fixed-rate agency MBS. Such transactions involve effectively delaying (or “rolling”) the settlement of a forward purchase of a TBA agency MBS by entering into an offsetting sale with the same counterparty prior to the settlement date, net settling the “paired-off” positions in cash, and contemporaneously entering, with the same counterparty, another forward purchase of a TBA agency MBS of the same characteristics for a later settlement date. TBA securities purchased for a forward settlement month are generally priced at a discount relative to TBA securities sold for settlement in the current month. This discount, often referred to as the dollar roll “price drop,” reflects compensation for the net interest income (interest income less financing costs) that is foregone as a result of relinquishing beneficial ownership of the MBS for the duration of the dollar roll (also known as “dollar roll income”). By executing a sequential series of dollar roll transactions, the Company is able to create the economic experience of investing in an agency MBS, financed with a repurchase agreement, over a period of time. Forward purchases and sales of TBA securities are accounted for as derivative instruments in the Company’s financial statements. Accordingly, dollar roll income is recognized as a component of “investment gain (loss), net” along with all other periodic changes in the fair value of TBA commitments. In addition to transacting in net long positions in TBA securities for investment purposes, the Company may also, from time to time, transact in net sale (or “net short”) positions in TBA securities for the purpose of economically hedging a portion of the sensitivity of the fair value of the Company’s investments in agency MBS to changes in interest rates. In addition to TBA transactions, the Company may, from time to time, enter into commitments to purchase or sell specified agency MBS that do not qualify as regular-way security trades. Such commitments are also accounted for as derivative instruments. Under the terms of commitments to purchase or sell TBA or specified agency MBS, the daily exchange of variation margin may occur based on changes in the fair value of the underlying agency MBS if a party to the transaction demands it. Receivables recognized for the right to reclaim cash collateral posted by the Company in respect of agency MBS purchase or sale commitments is included in the line item “deposits” in the accompanying consolidated balance sheets. Liabilities recognized for the obligation to return cash collateral received by the Company in respect of agency MBS purchase or sale commitments is included in the line item “other liabilities” in the accompanying consolidated balance sheets. Derivative Instrument Population and Fair Value The following table presents the fair value of the Company’s derivative instruments as of the dates indicated: March 31, 2020 December 31, 2019 Assets Liabilities Assets Liabilities Interest rate swaps $ 26 $ (55 ) $ 1,417 $ (8 ) TBA commitments 16,937 (11,773 ) — — Total $ 16,963 $ (11,828 ) $ 1,417 $ (8 ) Interest Rate Swaps The Company’s interest rate swap agreements represent agreements to make semiannual interest payments based upon a fixed interest rate and receive quarterly variable interest payments based upon the prevailing three-month LIBOR on the date of reset. The following table presents information about the Company’s interest rate swap agreements that were in effect as of March 31, 2020: Weighted-average: Notional Amount Fixed Pay Rate Variable Receive Rate Net Receive (Pay) Rate Remaining Life (Years) Fair Value Years to maturity: Less than 3 years $ 500,000 1.78 % 1.65 % (0.13 )% 1.0 $ (49 ) 3 to less than 5 years 100,000 1.52 % 0.77 % (0.75 )% 4.7 20 Total / weighted-average $ 600,000 1.73 % 1.50 % (0.23 )% 1.6 $ (29 ) The following table presents information about the Company’s interest rate swap agreements that were in effect as of December 31, 2019: Weighted-average: Notional Amount Fixed Pay Rate Variable Receive Rate Net Receive (Pay) Rate Remaining Life (Years) Fair Value Years to maturity: Less than 3 years $ 2,050,000 1.77 % 1.92 % 0.15 % 1.6 $ 83 3 to less than 7 years 510,000 1.61 % 1.92 % 0.31 % 6.0 439 7 to less than 10 years 400,000 2.24 % 1.91 % (0.33 )% 9.5 715 10 or more years 25,000 2.96 % 1.90 % (1.06 )% 28.2 172 Total / weighted-average $ 2,985,000 1.81 % 1.92 % 0.11 % 3.6 $ 1,409 U.S. Treasury Note Futures The Company may purchase or sell exchange-traded U.S. Treasury note futures with the objective of economically hedging a portion of its interest rate risk. Upon the maturity date of these futures contracts, the Company has the option to either net settle each contract in cash in an amount equal to the difference between the then-current fair value of the underlying U.S. Treasury note and the contractual sale price inherent to the futures contract, or to physically settle the contract by delivering the underlying U.S. Treasury note As of March 31, 2020 and December 31, 2019, the Company held no U.S. Treasury note futures. TBA Commitments The following table presents information about the Company’s TBA commitments as of the date indicated: March 31, 2020 Notional Amount: Purchase (Sale) Commitment Contractual Forward Price Market Price Fair Value 2.5% 30-year MBS purchase commitments $ 450,000 $ 451,422 $ 465,961 $ 14,539 2.5% 30-year MBS sale commitments (450,000 ) (455,930 ) (465,961 ) (10,031 ) 3.0% 30-year MBS purchase commitments 100,000 102,477 104,875 2,398 3.0% 30-year MBS sale commitments (100,000 ) (103,133 ) (104,875 ) (1,742 ) Total TBA commitments, net $ — $ (5,164 ) $ — $ 5,164 As of December 31, 2019, the Company had no outstanding TBA commitments. Derivative Instrument Gains and Losses The following tables provide information about the derivative gains and losses recognized within the periods indicated: Three Months Ended March 31, 2020 2019 Interest rate derivatives: Interest rate swaps: Net interest income (1) $ 592 $ 4,747 Unrealized gains (losses), net 5,945 (63,491 ) (Losses) gains realized upon early termination, net (109,924 ) 1,178 Total interest rate swap (losses) gains, net (103,387 ) (57,566 ) U.S. Treasury note futures, net (3,071 ) (6,704 ) Total interest rate derivative (losses) gains, net (106,458 ) (64,270 ) TBA commitments: TBA dollar roll income (2) 105 1,420 Other gains on TBA commitments, net 4,793 7,645 Total gains on TBA commitments, net 4,898 9,065 Other derivatives (1,040 ) — Total derivative losses, net $ (102,600 ) $ (55,205 ) (1) Represents the periodic net interest settlement incurred during the period (often referred to as “net interest carry”). Also includes “price alignment interest” income earned or expense incurred on cumulative variation margin paid or received, respectively, associated with centrally cleared interest rate swap agreements. (2) Represents the price discount of forward-settling TBA purchases relative to a contemporaneously executed “spot” TBA sale, which economically equates to net interest income that is earned ratably over the period beginning on the settlement date of the sale and ending on the settlement date of the forward-settling purchase. Derivative Instrument Activity The following tables summarize the volume of activity, in terms of notional amount, related to derivative instruments for the periods indicated: For the Three Months Ended March 31, 2020 Beginning of Period Additions Scheduled Settlements Early Terminations End of Period Interest rate swaps $ 2,985,000 $ — $ (100,000 ) $ (2,285,000 ) $ 600,000 2-year U.S. Treasury note futures — 1,150,000 — (1,150,000 ) — 10-year U.S. Treasury note futures — 765,000 — (765,000 ) — TBA purchase (sale) commitments, net — 100,000 (100,000 ) — — Put options on S&P 500 ETF — 1,850 (1,850 ) — — For the Three Months Ended March 31, 2019 Beginning of Period Additions Scheduled Settlements Early Terminations End of Period Interest rate swaps $ 3,100,000 $ 400,000 $ — $ (650,000 ) $ 2,850,000 10-year U.S. Treasury note futures 320,000 440,000 (390,000 ) (155,000 ) 215,000 TBA purchase (sale) commitments, net — 2,150,000 (1,250,000 ) — 900,000 Cash Collateral Posted and Received for Derivative and Other Financial Instruments The following table presents information about the cash collateral posted by the Company in respect of its derivative and other financial instruments, which is included in the line item “deposits, net” in the accompanying consolidated balance sheets, for the dates indicated: March 31, 2020 December 31, 2019 Cash collateral posted for: Interest rate swaps (cash initial margin) $ 4,569 $ 37,122 Unsettled MBS trades and TBA commitments, net 28,439 1 Total cash collateral posted, net $ 33,008 $ 37,123 As of March 31, 2020, the Company had pledged $1,506 in fair value of agency MBS in respect of its unsettled MBS trades. |
Offsetting of Financial Assets
Offsetting of Financial Assets and Liabilities | 3 Months Ended |
Mar. 31, 2020 | |
Offsetting [Abstract] | |
Offsetting of Financial Assets and Liabilities | Note 8. Offsetting of Financial Assets and Liabilities The agreements that govern certain of the Company’s derivative instruments and collateralized short-term financing arrangements provide for a right of setoff in the event of default or bankruptcy with respect to either party to such transactions. The Company presents derivative assets and liabilities as well as collateralized short-term financing arrangements on a gross basis. Receivables recognized for the right to reclaim cash initial margin posted in respect of interest rate derivative instruments are included in the line item “deposits” in the accompanying consolidated balance sheets. The daily exchange of variation margin associated with a centrally cleared or exchange-traded derivative instrument is legally characterized as the daily settlement of the derivative instrument itself, as opposed to a pledge of collateral. Accordingly, the Company accounts for the daily receipt or payment of variation margin associated with its interest rate swaps and futures as a direct reduction to the carrying value of the interest rate swap derivative asset or liability, respectively. The carrying amount of interest rate swaps and futures reflected in the Company’s consolidated balance sheets is equal to the unsettled fair value of such instruments; because variation margin is exchanged on a one-day lag, the unsettled fair value of such instruments generally represents the change in fair value that occurred on the last day of the reporting period. The following tables present information, as of the dates indicated, about the Company’s derivative instruments, short-term borrowing arrangements, and associated collateral, including those subject to master netting (or similar) arrangements: As of March 31, 2020 Gross Amount Recognized Amount Offset in the Consolidated Balance Sheets Net Amount Presented in the Consolidated Balance Sheets Gross Amount Not Offset in the Consolidated Balance Sheets Net Amount Financial Instruments (1) Cash Collateral (2) Assets: Derivative instruments: Interest rate swaps $ 26 $ — $ 26 $ (4 ) $ — $ 22 TBA commitments 16,937 — 16,937 (11,773 ) — 5,164 Total derivative instruments 16,963 — 16,963 (11,777 ) — 5,186 Total assets $ 16,963 $ — $ 16,963 $ (11,777 ) $ — $ 5,186 Liabilities: Derivative instruments: Interest rate swaps $ 55 $ — $ 55 $ (4 ) $ (51 ) $ — TBA commitments 11,773 — 11,773 (11,773 ) — — Total derivative instruments 11,828 — 11,828 (11,777 ) (51 ) — Repurchase agreements 2,036,466 — 2,036,466 (2,036,466 ) — — Total liabilities $ 2,048,294 $ — $ 2,048,294 $ (2,048,243 ) $ (51 ) $ — As of December 31, 2019 Gross Amount Recognized Amount Offset in the Consolidated Balance Sheets Net Amount Presented in the Consolidated Balance Sheets Gross Amount Not Offset in the Consolidated Balance Sheets Net Amount Financial Instruments (1) Cash Collateral (2) Assets: Derivative instruments: Interest rate swaps $ 1,417 $ — $ 1,417 $ — $ — $ 1,417 Total derivative instruments 1,417 — 1,417 — — 1,417 Total assets $ 1,417 $ — $ 1,417 $ — $ — $ 1,417 Liabilities: Derivative instruments: Interest rate swaps $ 8 $ — $ 8 $ (8 ) $ — $ — Total derivative instruments 8 — 8 (8 ) — — Repurchase agreements 3,581,237 — 3,581,237 (3,581,237 ) — — Total liabilities $ 3,581,245 $ — $ 3,581,245 $ (3,581,245 ) $ — $ — (1) Does not include the fair value amount of financial instrument collateral pledged in respect of repurchase agreements that exceeds the associated liability presented in the consolidated balance sheets. (2) Does not include the amount of cash collateral pledged in respect of derivative instruments that exceeds the associated derivative liability presented in the consolidated balance sheets. |
Fair Value Measurements
Fair Value Measurements | 3 Months Ended |
Mar. 31, 2020 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | Note 9. Fair Value Measurements Fair Value of Financial Instruments The accounting principles related to fair value measurements define fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Financial Accounting Standards Board Accounting Standards Codification Topic 820, Fair Value Measurements and Disclosures Level 1 Inputs - Unadjusted quoted prices in active markets for identical assets or liabilities that are accessible by the Company at the measurement date; Level 2 Inputs - Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly; and Level 3 Inputs - Unobservable inputs for the asset or liability, including significant judgments made by the Company about the assumptions that a market participant would use. The Company measures the fair value of the following assets and liabilities: Mortgage investments Agency MBS - The Company’s investments in agency MBS are classified within Level 2 of the fair value hierarchy. Inputs to fair value measurements of the Company’s investments in agency MBS include price estimates obtained from third-party pricing services. In determining fair value, third-party pricing services use a market approach. The inputs used in the fair value measurements performed by the third-party pricing services are based upon readily observable transactions for securities with similar characteristics (such as issuer/guarantor, coupon rate, stated maturity, and collateral pool characteristics) occurring on the measurement date. The Company makes inquiries of the third-party pricing sources to understand the significant inputs and assumptions used to determine prices. The Company reviews the various third-party fair value estimates and performs procedures to validate their reasonableness, including comparison to recent trading activity for similar securities and an overall review for consistency with market conditions observed as of the measurement date. Non-agency MBS - Most of the Company’s investments in non-agency MBS are CMBS that are classified within Level 2 of the fair value hierarchy. Inputs to fair value measurements of the Company’s investments in CMBS include quoted prices for similar assets in recent market transactions and estimates obtained from third-party pricing sources including pricing services and dealers. In determining fair value, third-party pricing sources use a market approach. The inputs used in the fair value measurements performed by third-party pricing sources are based upon observable transactions for CMBS with similar characteristics. The Company reviews the third-party fair value estimates and performs procedures to validate their reasonableness, including comparisons to recent trading activity observed for similar securities as well as performs a comparison to an internally derived discounted future cash flow measurement. The Company’s non-agency RMBS investment is classified within Level 3 of the fair value hierarchy. To measure the fair value of its non-agency RMBS investment, the Company uses an income approach by preparing an estimate of the present value of the amount and timing of the cash flows expected to be collected from the security over its expected remaining life o prepare the estimate of cash flows expected to be collected, the Company uses significant judgment to develop assumptions about the future performance of the pool of business-purpose residential mortgage loans that serve as collateral, including assumptions about the timing and amount of credit losses and prepayments March 31, 2020 Annualized default rate 7.3 % Loss-given-default 40.0 % Discount rate 10.1 % Mortgage loans – The Company’s investment in a mortgage loan is classified within Level 3 of the fair value hierarchy. To measure the fair value of its mortgage loan investment, the Company uses an income approach by preparing an estimate of the present value of the expected future cash flows of the mortgage loan over its expected remaining life, discounted at a current market rate. The significant unobservable inputs to the fair value measurement are the estimated remaining life of the mortgage loan and the discount rate, which is based on current market yields and interest rate spreads for similar mortgage loans. As of March 31, 2020, the estimated remaining life of the mortgage loan was 1.75 years and the discount rate used to measure the present value of estimated future cash flows was 6.9%. As of December 31, 2019, the fair value of the Company’s mortgage loan investment was its price of purchase, which occurred on the measurement date. Derivative instruments Exchange-traded derivative instruments - Exchange-traded derivative instruments, which include U.S. Treasury note futures, Eurodollar futures, interest rate swap futures, and options on futures, are classified within Level 1 of the fair value hierarchy as they are measured using quoted prices for identical instruments in liquid markets. Interest rate swaps - Interest rate swaps are classified within Level 2 of the fair value hierarchy. The fair values of the Company’s centrally cleared interest rate swaps are measured using the daily valuations reported by the clearinghouse through which the instrument was cleared. In performing its end-of-day valuations, the clearinghouse constructs forward interest rate curves (for example, three-month LIBOR forward rates) from its specific observations of that day’s trading activity. The clearinghouse uses the applicable forward interest rate curve to develop a market-based forecast of future remaining contractually required cash flows for each interest rate swap. Each market-based cash flow forecast is then discounted using the overnight index swap rate curve (sourced from the Federal Reserve Bank of New York) to determine a net present value amount which represents the instrument’s fair value. Forward-settling purchases and sales of TBA securities – Forward-settling purchases and sales of TBA securities are classified within Level 2 of the fair value hierarchy. The fair value of each forward-settling TBA contract is measured using price estimates obtained from a third-party pricing service, which are based upon readily observable transaction prices occurring on the measurement date for forward-settling contracts to buy or sell TBA securities with the same guarantor, contractual maturity, and coupon rate for delivery on the same forward settlement date as the commitment under measurement. Other Long-term unsecured debt - As of March 31, 2020 and December 31, 2019, the carrying value of the Company’s long-term unsecured debt was $74,383 and $74,328, respectively, net of unamortized debt issuance costs, and consists of Senior Notes and trust preferred debt issued by the Company. The Company’s estimate of the fair value of long-term unsecured debt is $54,766 and $70,429 as of March 31, 2020 and December 31, 2019, respectively. The Company’s Senior Notes, which are publicly traded on the New York Stock Exchange, are classified within Level 1 of the fair value hierarchy. Trust preferred debt is classified within Level 2 of the fair value hierarchy as the fair value is estimated based on the quoted prices of the Company’s publicly traded Senior Notes. Investments in equity securities of non-public companies and investment funds – As of March 31, 2020 and December 31, 2019, the Company had investment in equity securities and investment funds measured at fair value of $5,812 and $6,375, respectively, which is included in the line item “other assets” in the accompanying consolidated balance sheets. Investments in equity securities and investment funds are classified within Level 3 of the fair value hierarchy. The fair values of the Company’s investments in equity securities and investment funds are not readily determinable. Accordingly, for its investments in equity securities, the Company estimates fair value by estimating the enterprise value of the investee which it then allocates to the investee’s securities in the order of their preference relative to one another. To estimate the enterprise value of the investee, the Company uses traditional valuation methodologies based on income and market approaches, including the consideration of recent investments in, or tender offers for, the equity securities of the investee, a discounted cash flow analysis and a comparable guideline public company valuation. The primary unobservable inputs used in estimating the fair value of an equity security of a non-public company include (i) a stock price to net asset multiple for similar public companies that is applied to the entity’s net assets, (ii) a discount factor for lack of marketability and control, and (iii) a cost of equity discount rate, used to discount to present value the equity cash flows available for distribution and the terminal value of the entity. As of March 31, 2020, the stock price to net asset multiple for similar public companies, the discount factor for lack of marketability and control, and the cost of equity discount rate used as inputs were 67 percent, 9 percent, and 12 percent, respectively. As of December 31, 2019, the stock price to net asset multiple for similar public companies, the discount factor for lack of marketability and control, and the cost of equity discount rate used as inputs were 95 percent, 9 percent, and 12 percent, respectively. For its investments in investment funds, the Company estimates fair value based upon the investee’s net asset value per share. Financial assets and liabilities for which carrying value approximates fair value - Cash and cash equivalents, deposits, receivables, repurchase agreements, payables, and other assets and liabilities are generally reflected in the consolidated balance sheets at their cost, which, due to the short-term nature of these instruments and their limited inherent credit risk, approximates fair value. Fair Value Hierarchy Financial Instruments Measured at Fair Value on a Recurring Basis The following tables set forth financial instruments measured at fair value by level within the fair value hierarchy as of March 31, 2020 and December 31, 2019. Assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. March 31, 2020 Total Level 1 Level 2 Level 3 Agency MBS $ 645,001 $ — $ 645,001 $ — Non-agency MBS 32,623 — 23,457 9,166 Mortgage loans 44,614 — — 44,614 Derivative assets 16,963 — 16,963 — Derivative liabilities (11,828 ) — (11,828 ) — Other assets 5,812 — — 5,812 Total $ 733,185 $ — $ 673,593 $ 59,592 December 31, 2019 Total Level 1 Level 2 Level 3 Agency MBS $ 3,768,496 $ — $ 3,768,496 $ — Non-agency MBS 33,501 — 33,478 23 Mortgage loans 45,000 — — 45,000 Derivative assets 1,417 — 1,417 — Derivative liabilities (8 ) — (8 ) — Other assets 6,375 — — 6,375 Total $ 3,854,781 $ — $ 3,803,383 $ 51,398 Level 3 Financial Assets and Liabilities The table below sets forth an attribution of the change in the fair value of the Company’s Level 3 investments that are measured at fair value on a recurring basis for the periods indicated: Three Months Ended March 31, 2020 2019 Beginning balance $ 51,398 $ 6,139 Included in investment gain (loss), net (3,609 ) (156 ) Purchases 11,995 — Sales — — Payments, net (410 ) (80 ) Accretion of discount 218 1 Ending balance $ 59,592 $ 5,904 Net unrealized gains (losses) included in earnings for the period for Level 3 assets still held at the reporting date $ (3,609 ) $ (156 ) |
Income Taxes
Income Taxes | 3 Months Ended |
Mar. 31, 2020 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Note 10. Income Taxes The Company intends to elect to be taxed as a REIT under the Internal Revenue Code upon filing its tax return for its taxable year ended December 31, 2019. As a REIT, the Company will be required to distribute annually 90% of its REIT taxable income. So long as the Company continues to qualify as a REIT, it will generally not be subject to U.S. Federal or state corporate income taxes on its taxable income to the extent that it distributes all of its annual taxable income to its shareholders on a timely basis. At present, it is the Company’s intention to distribute 100% of its taxable income, although the Company will not be required to do so. The Company intends to make distributions of its taxable income within the time limits prescribed by the Internal Revenue Code, which may extend into the subsequent taxable year. For the Company’s tax years ended December 31, 2018 and earlier, the Company was taxed as a C corporation for U.S. federal tax purposes. As of March 31, 2020, the Company had estimated net operating loss (“NOL”) carryforwards of $14,588 that can be used to offset future taxable ordinary income. The Company’s NOL carryforwards begin to expire in 2028. As of March 31, 2020, the Company had estimated net capital loss (“NCL”) carryforwards of $258,633 that can be used to offset future net capital gains. The scheduled expirations of the Company’s NCL carryforwards are $77,685 in 2020, $66,862 in 2021, $3,763 in 2022 and $110,323 in 2023. Through December 31, 2017, the Company was subject to federal alternative minimum tax (“AMT”) on its taxable income and gains that were not offset by its NOL and NCL carryforwards with any AMT credit carryforwards available to offset future regular tax liabilities. As part of the Tax Cuts and Jobs Act of 2017, the corporate AMT was repealed for tax years beginning after December 31, 2017 with any AMT credit carryforward after that date continuing to be available to offset a taxpayer’s future regular tax liability. In addition, for tax years beginning in 2018, 2019 and 2020, to the extent that AMT credit carryforwards exceed the regular tax liability, 50% of the excess AMT credit carryforwards would be refundable upon the filing of the income tax return for that year with any remaining AMT credit carryforwards fully refundable upon the filing of the 2021 income tax return. As part of the Coronavirus Aid, Relief, and Economic Security Act of 2020 (the “Cares Act”), the timing of the refunding of the full amount of excess AMT credit carryforwards was accelerated so that it can now be refunded immediately. As a result, the Company filed a request for a full refund of its remaining excess AMT credit that it expects to receive during 2020. As of March 31, 2020 and December 31, 2019, the Company had an AMT credit carryforward of $4,566, included as a receivable in “other assets” on the accompanying consolidated balance sheets. The Company recognizes uncertain tax positions in the financial statements only when it is more-likely-than-not that the position will be sustained upon examination by the relevant taxing authority based on the technical merits of the position. A position that meets this standard is measured On May 29, 2018, the Company received an assessment of $9,380 from Arlington County, Virginia for a business, professional and occupation license (“BPOL”) tax for 2018. The BPOL tax is a local privilege tax on a business’ gross receipts for conducting business activities subject to licensure within a county in Virginia. The Company had not been assessed or paid any such BPOL tax prior to 2018. On June 28, 2018, the Company filed an administrative appeal with Arlington County. On August 1, 2018, the Company received a denial of its administrative appeal from Arlington County and, subsequently, the Company filed an administrative appeal with the Tax Commissioner of Virginia (the “Tax Commissioner”) on September 27, 2018. On June 21, 2019, the Company received a determination from the Tax Commissioner stating that he believes the Company is engaged in a licensable privilege subject to the BPOL tax. The Tax Commissioner requested that Arlington County revise its initial BPOL tax assessment to exclude certain gross receipts from its tax calculation. On August 21, 2019, the Company received a revised 2018 BPOL tax assessment of $488, including interest charges, as well as a 2019 BPOL tax assessment of $471 from Arlington County both of which the Company paid on September 3, 2019. On September 30, 2019, the Company relocated its corporate headquarters from Arlington County to Fairfax County, Virginia. As a result, the Company received a partial refund of its 2019 BPOL tax of $118 from Arlington County while also recognizing a partial year 2019 BPOL tax assessment of $54 to Fairfax County. For the year ended December 31, 2019, the Company recognized an expense of $892 in “other general and administrative expense” which represents the 2018 and 2019 BPOL tax (and associated interest). The Company retains the right to appeal the Tax Commissioner’s determination through June of 2020. BPOL tax for the 2017 year remains subject to examination by Arlington County, although the county has previously informally indicated that it did not intend to pursue assessments for that year at such time. |
Earnings (Loss) Per Share
Earnings (Loss) Per Share | 3 Months Ended |
Mar. 31, 2020 | |
Earnings Per Share [Abstract] | |
Earnings (Loss) Per Share | Note 11. Earnings (Loss) Per Share Basic earnings (loss) per share includes no dilution and is computed by dividing net income or loss applicable to common stock by the weighted-average number of common shares outstanding for the respective period. Diluted earnings per share includes the impact of dilutive securities such as unvested shares of restricted stock, restricted stock units, and performance share units. The following tables present the computations of basic and diluted earnings (loss) per share for the periods indicated: Three Months Ended March 31, (Shares in thousands) 2020 2019 Basic weighted-average common shares outstanding 36,711 33,053 Performance share units, unvested restricted stock units, and unvested restricted stock — 86 Diluted weighted-average common shares outstanding 36,711 33,139 Net (loss) income (attributable) available to common stock $ (94,944 ) $ 17,316 Basic (loss) earnings per common share $ (2.59 ) $ 0.52 Diluted (loss) earnings per common share $ (2.59 ) $ 0.52 The diluted loss per share for the three months ended March 31, 2020 did not include the antidilutive effect of 106 shares of unvested shares of restricted stock, restricted stock units, and performance share units. |
Stockholders' Equity
Stockholders' Equity | 3 Months Ended |
Mar. 31, 2020 | |
Equity [Abstract] | |
Stockholders' Equity | Note 12. Stockholders’ Equity Common Stock The Company has authorized common share capital of 450,000,000 shares of Class A common stock, par value $0.01 per share, and 100,000,000 shares of Class B common stock, par value $0.01 per share. Holders of the Class A and Class B common stock are entitled to one vote and three votes per share, respectively, on all matters voted upon by the shareholders. Shares of Class B common stock are convertible into shares of Class A common stock on a one-for-one basis at the option of the Company in certain circumstances including either (i) upon sale or other transfer, or (ii) at the time the holder of such shares of Class B common stock ceases to be employed by the Company. As of March 31, 2020 and December 31, 2019, there were no outstanding shares of Class B common stock. The Class A common stock is publicly traded on the New York Stock Exchange under the ticker symbol “AI.” Common Stock Dividends The Board of Directors evaluates common stock dividends on a quarterly basis and, in its sole discretion, approves the payment of dividends. The Company’s common stock dividend payments, if any, may vary significantly from quarter to quarter. For the quarter ended March 31, 2020, the Board of Directors determined that the Company would not declare a dividend on its common stock. The Board of Directors approved and the Company declared and paid the following dividends on its common stock for 2019: Quarter Ended Dividend Amount Declaration Date Record Date Pay Date December 31 $ 0.225 December 13 December 31 February 3, 2020 September 30 0.225 September 17 September 30 October 31 June 30 0.225 June 24 July 5 July 31 March 31 0.375 March 18 March 29 April 30 For REIT qualification purposes, the common stock dividend of $0.225 per share declared on December 13, 2019 and paid on February 3, 2020 is considered a distribution of taxable income for tax year 2020. As such, this dividend is applicable to the Company’s REIT taxable income distribution requirements for tax year 2020. Common Equity Offerings On February 22, 2019, the Company completed a public offering in which 6,000,000 shares of its Class A common stock were sold at a price of $8.16 per share for proceeds net of offering expenses of $48,827. Common Equity Distribution Agreements On February 22, 2017, the Company entered into separate common equity distribution agreements with equity sales agents JMP Securities LLC, FBR Capital Markets & Co., JonesTrading Institutional Services LLC and Ladenburg Thalmann & Co. Inc. pursuant to which the Company may offer and sell, from time to time, up to 6,000,000 shares of the Company’s Class A common stock. Pursuant to the common equity distribution agreements, shares of the Company’s common stock may be offered and sold through the equity sales agents in transactions that are deemed to be “at the market” offerings as defined in Rule 415 under the Securities Act of 1933, including sales made directly on the NYSE or sales made to or through a market maker other than on an exchange or, subject to the terms of a written notice from the Company, in privately negotiated transactions. During the three months ended March 31, 2020 and the year ended December 31, 2019, there were no issuances of common stock under the common equity distribution agreements. As of March 31, 2020, the Company had 11,302,160 shares of Class A common stock available for sale under the common equity distribution agreements. Common Share Repurchase Program The Company’s Board of Directors authorized a share repurchase program pursuant to which the Company may repurchase up to 2,000,000 shares of Class A common stock (the “Repurchase Program”). Repurchases under the Repurchase Program may be made from time to time on the open market and in private transactions at management’s discretion in accordance with applicable federal securities laws. The timing of repurchases and the exact number of shares of Class A common stock to be repurchased will depend upon market conditions and other factors. The Repurchase Program is funded using the Company’s cash on hand and cash generated from operations. The Repurchase Program has no expiration date and may be suspended or terminated at any time without prior notice. There were no shares repurchased by the Company under the Repurchase Program during the three months ended March 31, 2020 and the year ended December 31, 2019. As of March 31, 2020, there remain available for repurchase 1,951,305 shares of Class A common stock under the Repurchase Program. Preferred Stock The Company has authorized preferred share capital of (i) 100,000 shares designated as Series A Preferred Stock that is unissued; (ii) 2,000,000 shares designated as 7.00% Series B Cumulative Perpetual Redeemable Preferred Stock (the “Series B Preferred Stock”), par value of $0.01 per share; (iii) 2,500,000 shares designated as 8.250% Series C Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock (the “Series C Preferred Stock”), par value of $0.01 per share; and (iv) 20,400,000 shares of undesignated preferred stock. The Company’s Board of Directors has the authority, without further action by the shareholders, to issue additional preferred stock in one or more series and to fix the terms and rights of the preferred stock. The Company’s preferred stock ranks senior to its common stock with respect to the payment of dividends and the distribution of assets upon a voluntary or involuntary liquidation, dissolution, or winding up of the Company. The Company’s preferred stock ranks on parity with each other. The Series B Preferred Stock and Series C Preferred Stock are publicly traded on the New York Stock Exchange under the ticker symbols “AI PrB” and “AI PrC,” respectively. The Series B Preferred Stock has no stated maturity, is not subject to any sinking fund and will remain outstanding indefinitely unless repurchased or redeemed by the Company. Holders of Series B Preferred Stock have no voting rights, except under limited conditions, and are entitled to receive a cumulative cash dividend at a rate of 7.00% per annum of their $25.00 per share liquidation preference (equivalent to $1.75 per annum per share). Shares of Series B Preferred Stock are redeemable at $25.00 per share, plus accumulated and unpaid dividends (whether or not authorized or declared), exclusively at the Company’s option commencing on May 12, 2022 or earlier upon the occurrence of a change in control. Dividends are payable quarterly in arrears on the 30th day of March, June, September and December of each year, when and as declared. The Company has declared and paid all required quarterly dividends on the Company’s Series B Preferred Stock to date in 2020. On March 12, 2019, the Company completed an initial public offering in which 1,200,000 shares of its Series C Preferred Stock were issued to the public at a public offering price of $25.00 per share for proceeds net of underwriting discounts and commissions and expenses of $28,944. The Series C Preferred Stock has no stated maturity, is not subject to any sinking fund and will remain outstanding indefinitely unless repurchased or redeemed by the Company. Holders of Series C Preferred Stock have no voting rights, except under limited conditions, and are entitled to receive a cumulative cash dividend (i) from and including the original issue date to, but excluding, March 30, 2024 at a fixed rate equal to 8.250% per annum of the $25.00 per share liquidation preference (equivalent to $2.0625 per annum per share) and (ii) from and including March 30, 2024, at a floating rate equal to three-month LIBOR plus a spread of 5.664% per annum of the $25.00 per share liquidation preference. Shares of Series C Preferred Stock are redeemable at $25.00 per share, plus accumulated and unpaid dividends (whether or not authorized or declared), exclusively at the Company’s option commencing on March 30, 2024 or earlier upon the occurrence of a change in control or under circumstances where it is necessary to preserve the Company’s qualification as a REIT. Dividends will be payable quarterly in arrears on the 30th day of March, June, September and December of each year, when and as declared, beginning on June 30, 2019. The Company has declared and paid all required quarterly dividends on the Company’s Series C Preferred Stock to date in 2020. Preferred Equity Distribution Agreements On May 16, 2017, the Company entered into an equity distribution agreement with JonesTrading Institutional Services LLC, pursuant to which the Company may offer and sell, from time to time, up to 1,865,000 shares of the Company’s Series B Preferred Stock. On March 21, 2019, the Company entered into an amended and restated equity distribution agreement with JonesTrading Institutional Services LLC, B. Riley FBR, Inc., Compass Point Research and Trading, LLC and Ladenburg Thalmann & Co. Inc., pursuant to which the Company may offer and sell, from time to time, up to 1,647,370 shares of the Company’s Series B Preferred Stock. Pursuant to the Series B preferred equity distribution agreement, shares of the Company’s Series B Preferred stock may be offered and sold through the preferred equity sales agents in transactions that are deemed to be “at the market” offerings as defined in Rule 415 under the Securities Act of 1933, including sales made directly on the NYSE or sales made to or through a market maker other than on an exchange or, subject to the terms of a written notice from the Company, in privately negotiated transactions. During the three months ended March 31, 2020, there were no issuances of preferred stock under the Series B preferred equity distribution agreement. The following table provides information about the issuances of preferred stock under the Series B preferred equity distribution agreements for the period indicated: Series B Preferred Stock Issuances Year Ended December 31, 2019 Shares issued 3,444 Weighted average public offering price $ 22.39 Net proceeds (1) $ 76 (1) Net of selling commissions and expenses. As of March 31, 2020, the Company had 1,645,961 shares of Series B Preferred stock available for sale under the preferred equity distribution agreement. Shareholder Rights Agreement On June 1, 2009, the Board of Directors approved a shareholder rights agreement (“Rights Plan”) and the Company’s shareholders approved the Rights Plan at its annual meeting of shareholders on June 2, 2010. On April 9, 2018, the Board of Directors approved a first amendment to the Rights Plan (“First Amendment”) to extend the term for an additional three years and the Company’s shareholders approved the First Amendment at its annual meeting of shareholders on June 14, 2018. Under the terms of the Rights Plan, in general, if a person or group acquires or commences a tender or exchange offer for beneficial ownership of 4.9% or more of the outstanding shares of our Class A common stock upon a determination by our Board of Directors (an “Acquiring Person”), all of our other Class A and Class B common shareholders will have the right to purchase securities from us at a discount to such securities’ fair market value, thus causing substantial dilution to the Acquiring Person. The Board of Directors adopted the Rights Plan in an effort to protect against a possible limitation on the Company’s ability to use its NOL carryforwards, NCL carryforwards, and built-in losses under Sections 382 and 383 of the Code. The Company’s ability to use its NOLs, NCLs and built-in losses would be limited if it experienced an “ownership change” under Section 382 of the Code. In general, an “ownership change” would occur if there is a cumulative change in the ownership of the Company’s common stock of more than 50% by one or more “5% shareholders” during a three-year period. The Rights Plan was adopted to dissuade any person or group from acquiring 4.9% or more of the Company’s outstanding Class A common stock, each, an Acquiring Person, without the approval of the Board of Directors and triggering an “ownership change” as defined by Section 382. The Rights Plan, as amended, and any outstanding rights will expire at the earliest of (i) June 4, 2022, (ii) the time at which the rights are redeemed or exchanged pursuant to the Rights Plan, (iii) the repeal of Section 382 and 383 of the Code or any successor statute if the Board of Directors determines that the Rights Plan is no longer necessary for the preservation of the applicable tax benefits, or (iv) the beginning of a taxable year to which the Board of Directors determines that no applicable tax benefits may be carried forward. |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 3 Months Ended |
Mar. 31, 2020 | |
Cash Equivalents | Cash Equivalents Cash equivalents include demand deposits with banks, money market accounts and highly liquid investments with original maturities of three months or less. As of March 31, 2020 and December 31, 2019, approximately 99% and 97%, respectively, of the Company’s cash equivalents were invested in money market funds that invest primarily in U.S. Treasuries and other securities backed by the U.S. government. |
Investment Security Purchases and Sales | Investment Security Purchases and Sales Purchases and sales of investment securities are recorded on the settlement date of the transfer unless the trade qualifies as a “regular-way” trade and the associated commitment qualifies for an exemption from the accounting guidance applicable to derivative instruments. A regular-way trade is an investment security purchase or sale transaction that is expected to settle within the period of time following the trade date that is prevalent or traditional for that specific type of security. Any amounts payable or receivable for unsettled security trades are recorded as “sold securities receivable” or “purchased securities payable” in the consolidated balance sheets. |
Interest Income Recognition for Investments in Agency MBS | Interest Income Recognition for Investments in Agency MBS The Company recognizes interest income for its investments in agency MBS by applying the “interest method” permitted by GAAP, whereby purchase premiums and discounts are amortized and accreted, respectively, as an adjustment to contractual interest income accrued at each security’s stated coupon rate. The interest method is applied at the individual security level based upon each security’s effective interest rate. The Company calculates each security’s effective interest rate at the time of purchase by solving for the discount rate that equates the present value of that security's remaining contractual cash flows (assuming no principal prepayments) to its purchase price. Because each security’s effective interest rate does not reflect an estimate of future prepayments, the Company refers to this manner of applying the interest method as the “contractual effective interest method.” When applying the contractual effective interest method to its investments in agency MBS, as principal prepayments occur, a proportional amount of the unamortized premium or discount is recognized in interest income such that the contractual effective interest rate on the remaining security balance is unaffected. |
Interest Income Recognition for Investments in Non-Agency MBS | Interest Income Recognition for Investments in Non-Agency MBS The Company recognizes interest income for its investments in non-agency MBS by applying the prospective level-yield methodology required by GAAP for securitized financial assets that are either not of high credit quality at the time of acquisition or can be contractually prepaid or otherwise settled in such a way that the Company would not recover substantially all of its recorded investment. The amount of periodic interest income recognized is determined by applying the security’s effective interest rate to its amortized cost basis (or “reference amount”). At the time of acquisition, the security’s effective interest rate is calculated by solving for the single discount rate that equates the present value of the Company’s best estimate of the amount and timing of the cash flows expected to be collected from the security to its purchase price. To prepare its best estimate of cash flows expected to be collected, the Company develops a number of assumptions about the future performance of the pool of mortgage loans that serve as collateral for its investment, including assumptions about the timing and amount of prepayments and credit losses. In each subsequent quarterly reporting period, the amount and timing of cash flows expected to be collected from the security are re-estimated based upon current information and events. The following table provides a description of how periodic changes in the estimate of cash flows expected to be collected affect interest income recognition prospectively for investments in non-agency MBS: Scenario: Effect on Interest Income Recognition for Investments in Non-Agency MBS: A positive change in cash flows occurs. Actual cash flows exceed prior estimates and/or a positive change occurs in the estimate of expected remaining cash flows. A revised effective interest rate is calculated and applied prospectively such that the positive change in cash flows is recognized as incremental interest income over the remaining life of the security. The amount of periodic interest income recognized over the remaining life of the security will be reduced accordingly. Specifically, if an adverse change in cash flows occurs for a security that is impaired (that is, its fair value is less than its reference amount), the reference amount to which the security’s existing effective interest rate will be prospectively applied will be reduced to the present value of cash flows expected to be collected, discounted at the security’s existing effective interest rate. If an adverse change in cash flows occurs for a security that is not impaired, the security’s effective interest rate will be reduced accordingly and applied on a prospective basis. An adverse change in cash flows occurs. Actual cash flows fall short of prior estimates and/or an adverse change occurs in the estimate of expected remaining cash flows. |
Other Significant Accounting Policies | Other Significant Accounting Policies Certain of the Company’s other significant accounting policies are summarized in the following notes: Investments in agency MBS, subsequent measurement Note 3 Investments in non-agency MBS, subsequent measurement Investments in mortgage loans, subsequent measurement Borrowings Note 4 Note 5 Note 6 To-be-announced agency MBS transactions, including “dollar rolls” Note 7 Derivative instruments Note 7 Balance sheet offsetting Note 8 Fair value measurements Note 9 Refer to the Company’s 2019 Annual Report on Form 10-K for a complete inventory and summary of the Company’s significant accounting policies. |
Recent Accounting Pronouncements | Recent Accounting Pronouncements The following table provides a brief description of recently issued accounting pronouncements and their actual or expected effect on the Company’s consolidated financial statements: Standard Description Date of Adoption Effect on the Consolidated Financial Statements Recently Adopted Accounting Guidance ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 606) The amendments in this update require financial assets measured at amortized cost as well as available-for-sale debt securities to be measured for impairment on the basis of the net amount expected to be collected. Credit losses are to be recognized through an allowance for credit losses, which differs from the direct write-down of the amortized cost basis previously required for other-than-temporary impairments of investments in debt securities. This update also makes substantial changes to the manner in which interest income is to be recognized for financial assets acquired with a more-than-insignificant amount of credit deterioration since origination. This update does not affect the accounting for investments in debt securities that are classified as trading securities. January 1, 2020 All of the Company’s investments in debt securities are classified as trading securities. Accordingly, the adoption of ASU No. 2016-13 did not have an effect on the Company’s consolidated financial statements. Recently Issued Accounting Guidance Not Yet Adopted ASU No. 2020-04, Reference Rate Reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting The amendments in this update provide optional practical expedients and exceptions for applying GAAP to the modification of receivables, debt, or lease contracts as well as cash flow and fair value hedge accounting relationships that reference a rate, such as LIBOR, that is expected to be discontinued because of reference rate reform. The practical expedients and exceptions provided by the update are effective from March 12, 2020 through December 31, 2022. Not yet adopted. To date, the Company has not made any modifications to contracts due to reference rate reform. The Company has not elected to apply hedge accounting for financial reporting purposes. |
Repurchase Agreements | The Company finances the purchase of mortgage investments through repurchase agreements, which are accounted for as collateralized borrowing arrangements. In a repurchase transaction, the Company sells a mortgage investment to a counterparty under a master repurchase agreement in exchange for cash and concurrently agrees to repurchase the same asset at a future date in an amount equal to the cash initially exchanged plus an agreed-upon amount of interest. Mortgage investments sold under agreements to repurchase remain on the Company’s consolidated balance sheets because the Company maintains effective control over such assets throughout the duration of the arrangement. Throughout the contractual term of a repurchase agreement, the Company recognizes a “repurchase agreement” liability on its consolidated balance sheets to reflect the obligation to repay to the counterparty the proceeds received upon the initial transfer of the mortgage investment. The difference between the proceeds received by the Company upon the initial transfer of the mortgage investment and the contractually agreed-upon repurchase price is recognized as interest expense ratably over the term of the repurchase arrangement. |
Derivative Instruments | In the normal course of its operations, the Company is a party to financial instruments that are accounted for as derivative instruments. Derivative instruments are recorded at fair value as either “derivative assets” or “derivative liabilities” in the consolidated balance sheets, with all periodic changes in fair value reflected as a component of “investment gain (loss), net” in the consolidated statements of comprehensive income. Cash receipts or payments related to derivative instruments are classified as investing activities within the consolidated statements of cash flows. In addition to interest rate hedging instruments that are used for interest rate risk management, the Company is a party to derivative instruments that economically serve as investments, such as forward commitments to purchase fixed-rate “pass-through” agency MBS on a non-specified pool basis, which are known as to-be-announced (“TBA”) securities. A TBA security is a forward commitment for the purchase or sale of a fixed-rate agency MBS at a predetermined price, face amount, issuer, coupon, and stated maturity for settlement on an agreed upon future date. The specific agency MBS that will be delivered to satisfy the TBA trade is not known at the inception of the trade. The specific agency MBS to be delivered is determined 48 hours prior to the settlement date. The Company accounts for TBA securities as derivative instruments because the Company cannot assert that it is probable at inception and throughout the term of an individual TBA commitment that its settlement will result in physical delivery of the underlying agency MBS, or the individual TBA commitment will not settle in the shortest time period possible. |
Derivatives, Offsetting of Financial Assets and Liabilities | The agreements that govern certain of the Company’s derivative instruments and collateralized short-term financing arrangements provide for a right of setoff in the event of default or bankruptcy with respect to either party to such transactions. The Company presents derivative assets and liabilities as well as collateralized short-term financing arrangements on a gross basis. Receivables recognized for the right to reclaim cash initial margin posted in respect of interest rate derivative instruments are included in the line item “deposits” in the accompanying consolidated balance sheets. The daily exchange of variation margin associated with a centrally cleared or exchange-traded derivative instrument is legally characterized as the daily settlement of the derivative instrument itself, as opposed to a pledge of collateral. Accordingly, the Company accounts for the daily receipt or payment of variation margin associated with its interest rate swaps and futures as a direct reduction to the carrying value of the interest rate swap derivative asset or liability, respectively. The carrying amount of interest rate swaps and futures reflected in the Company’s consolidated balance sheets is equal to the unsettled fair value of such instruments; because variation margin is exchanged on a one-day lag, the unsettled fair value of such instruments generally represents the change in fair value that occurred on the last day of the reporting period. |
Fair Value of Financial Instruments | The accounting principles related to fair value measurements define fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Financial Accounting Standards Board Accounting Standards Codification Topic 820, Fair Value Measurements and Disclosures Level 1 Inputs - Unadjusted quoted prices in active markets for identical assets or liabilities that are accessible by the Company at the measurement date; Level 2 Inputs - Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly; and Level 3 Inputs - Unobservable inputs for the asset or liability, including significant judgments made by the Company about the assumptions that a market participant would use. The Company measures the fair value of the following assets and liabilities: |
Agency MBS | |
Investment Security Purchases and Sales | The Company has elected to classify its investments in agency MBS as trading securities. Accordingly, the Company’s investments in agency MBS are reported in the accompanying consolidated balance sheets at fair value . As of March 31, 2020 and December 31, 2019, the fair value of the Company’s investments in agency MBS was $645,001 and $3,768,496, respectively. |
Non-Agency MBS | |
Investment Security Purchases and Sales | The Company has elected to classify its investments in non-agency MBS as trading securities. Accordingly, the Company’s investments in non-agency MBS are reported in the accompanying consolidated balance sheets at fair value. As of March 31, 2020 and December 31, 2019, the fair value of the Company’s investments in non-agency MBS was $32,623 and $33,501, respectively. |
Mortgage Loans | |
Investment Security Purchases and Sales | The Company recognizes interest income on its mortgage loan investment based upon the contractual note rate of the loan. The Company has elected to account for its mortgage loan investment at fair value on a recurring basis with periodic changes in fair value recognized as a component of “investment gain (loss), net” in the accompanying consolidated statements of comprehensive income. |
Investments in Agency MBS (Tabl
Investments in Agency MBS (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Agency MBS | |
Additional Information Realized Gain Loss on Investments | The following table provides additional information about the gains and losses recognized as a component of “investment gain (loss), net” in the Company’s consolidated statements of comprehensive income for the periods indicated with respect to investments in agency MBS: Three Months Ended March 31, 2020 2019 Net gains (losses) recognized in earnings for: Agency MBS still held at period end $ 12,127 $ 62,109 Agency MBS sold during the period 11,391 7,056 Total $ 23,518 $ 69,165 |
Investments in Non-Agency MBS (
Investments in Non-Agency MBS (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Non-Agency MBS | |
Additional Information Realized Gain Loss on Investments | The following table provides additional information about the gains and losses recognized as a component of “investment gain (loss), net” in the Company’s consolidated statements of comprehensive income for the periods indicated with respect to investments in non-agency MBS: Three Months Ended March 31, 2020 2019 Net gains (losses) recognized in earnings for: Non-agency MBS still held at period end $ (15,618 ) $ 3 Non-agency MBS sold during the period (4,420 ) — Total $ (20,038 ) $ 3 |
Borrowings (Tables)
Borrowings (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Debt Disclosure [Abstract] | |
Schedule of Repurchase Agreements | The Company’s MBS repurchase agreement arrangements generally carry a fixed rate of interest and are short-term in nature with contract durations generally ranging from 30 to 60 days, but may be as short as one day or as long as one year. The Company’s mortgage loan repurchase agreement arrangement has a maturity date of February 9, 2021 and an interest rate that resets monthly at a rate equal to one-month LIBOR plus 2.00% with an interest rate floor of 3.00%. Under the terms of the Company’s mortgage loan repurchase agreement, the Company may request extensions of the maturity date of the agreement by up to 364 days, subject to the lender’s approval. As of March 31, 2020 and December 31, 2019, the Company had no amount at risk with a single repurchase agreement counterparty or lender greater than 10% of equity. The following table provides information regarding the Company’s outstanding repurchase agreement borrowings as of the dates indicated: March 31, 2020 December 31, 2019 Agency MBS repurchase financing: Repurchase agreements outstanding $ 1,977,095 $ 3,560,139 Agency MBS collateral, at fair value (1) 2,094,164 3,741,399 Net amount (2) 117,069 181,260 Weighted-average rate 0.92 % 2.10 % Weighted-average term to maturity 15.0 days 23.7 days Non-agency MBS repurchase financing: Repurchase agreements outstanding $ 27,871 $ 21,098 MBS collateral, at fair value (3) 41,230 30,747 Net amount (2) 13,359 9,649 Weighted-average rate 3.13 % 3.11 % Weighted-average term to maturity 5.3 days 8.1 days Mortgage loans repurchase financing: Repurchase agreements outstanding $ 31,500 $ — Mortgage loans collateral, at fair value 44,614 — Net amount (2) 13,114 — Weighted-average rate 3.00 % — Weighted-average term to maturity 315.0 days — Total mortgage investments repurchase financing: Repurchase agreements outstanding $ 2,036,466 $ 3,581,237 Mortgage investments collateral, at fair value 2,180,008 3,772,146 Net amount (2) 143,542 190,909 Weighted-average rate 0.98 % 2.11 % Weighted-average term to maturity 19.5 days 23.6 days (1) As of March 31, 2020 and December 31, 2019, includes $1,455,136 and $71,284, respectively, at sale price of unsettled agency MBS sale commitments which are included in the line item “sold securities receivable” in the accompanying consolidated balance sheets. (2) Net amount represents the value of collateral in excess of corresponding repurchase obligation. The amount of collateral at-risk is limited to the outstanding repurchase obligation and not the entire collateral balance. (3) As of March 31, 2020, includes $32,607 and $8,623 at fair value of non-agency and agency MBS collateral, respectively. As of December 31, 2019, includes $30,747 at fair value of non-agency MBS collateral. The following table provides information regarding the Company’s outstanding repurchase agreement borrowings during the three months ended March 31, 2020 and 2019: March 31, 2020 March 31, 2019 Weighted-average outstanding balance during the three months ended $ 3,162,340 $ 3,680,429 Weighted-average rate during the three months ended 1.83 % 2.68 % |
Schedule of Long-term Unsecured Debt Instruments | As of March 31, 2020 and December 31, 2019, the Company had $74,383 and $74,328, respectively, of outstanding long-term unsecured debentures, net of unamortized debt issuance costs of $917 and $972, respectively. The Company’s long-term debentures consisted of the following as of the dates indicated: March 31, 2020 December 31, 2019 Senior Notes Due 2025 Senior Notes Due 2023 Trust Preferred Debt Senior Notes Due 2025 Senior Notes Due 2023 Trust Preferred Debt Outstanding Principal $ 35,300 $ 25,000 $ 15,000 $ 35,300 $ 25,000 $ 15,000 Annual Interest Rate 6.75 % 6.625 % LIBOR+ 2.25 - 3.00 % 6.75 % 6.625 % LIBOR+ 2.25 - 3.00 % Interest Payment Frequency Quarterly Quarterly Quarterly Quarterly Quarterly Quarterly Weighted-Average Interest Rate 6.75 % 6.625 % 4.58 % 6.75 % 6.625 % 4.74 % Maturity March 15, 2025 May 1, 2023 2033 - 2035 March 15, 2025 May 1, 2023 2033 - 2035 |
Derivative Instruments (Tables)
Derivative Instruments (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | |
Schedule of Derivative Instruments | The following table presents the fair value of the Company’s derivative instruments as of the dates indicated: March 31, 2020 December 31, 2019 Assets Liabilities Assets Liabilities Interest rate swaps $ 26 $ (55 ) $ 1,417 $ (8 ) TBA commitments 16,937 (11,773 ) — — Total $ 16,963 $ (11,828 ) $ 1,417 $ (8 ) |
Schedule of Other Derivatives Not Designated as Hedging Instruments, Statements of Financial Performance and Financial Position, Location | The following tables provide information about the derivative gains and losses recognized within the periods indicated: Three Months Ended March 31, 2020 2019 Interest rate derivatives: Interest rate swaps: Net interest income (1) $ 592 $ 4,747 Unrealized gains (losses), net 5,945 (63,491 ) (Losses) gains realized upon early termination, net (109,924 ) 1,178 Total interest rate swap (losses) gains, net (103,387 ) (57,566 ) U.S. Treasury note futures, net (3,071 ) (6,704 ) Total interest rate derivative (losses) gains, net (106,458 ) (64,270 ) TBA commitments: TBA dollar roll income (2) 105 1,420 Other gains on TBA commitments, net 4,793 7,645 Total gains on TBA commitments, net 4,898 9,065 Other derivatives (1,040 ) — Total derivative losses, net $ (102,600 ) $ (55,205 ) (1) Represents the periodic net interest settlement incurred during the period (often referred to as “net interest carry”). Also includes “price alignment interest” income earned or expense incurred on cumulative variation margin paid or received, respectively, associated with centrally cleared interest rate swap agreements. (2) Represents the price discount of forward-settling TBA purchases relative to a contemporaneously executed “spot” TBA sale, which economically equates to net interest income that is earned ratably over the period beginning on the settlement date of the sale and ending on the settlement date of the forward-settling purchase. |
Derivative Instrument Volume of Activity | The following tables summarize the volume of activity, in terms of notional amount, related to derivative instruments for the periods indicated: For the Three Months Ended March 31, 2020 Beginning of Period Additions Scheduled Settlements Early Terminations End of Period Interest rate swaps $ 2,985,000 $ — $ (100,000 ) $ (2,285,000 ) $ 600,000 2-year U.S. Treasury note futures — 1,150,000 — (1,150,000 ) — 10-year U.S. Treasury note futures — 765,000 — (765,000 ) — TBA purchase (sale) commitments, net — 100,000 (100,000 ) — — Put options on S&P 500 ETF — 1,850 (1,850 ) — — For the Three Months Ended March 31, 2019 Beginning of Period Additions Scheduled Settlements Early Terminations End of Period Interest rate swaps $ 3,100,000 $ 400,000 $ — $ (650,000 ) $ 2,850,000 10-year U.S. Treasury note futures 320,000 440,000 (390,000 ) (155,000 ) 215,000 TBA purchase (sale) commitments, net — 2,150,000 (1,250,000 ) — 900,000 |
Derivative Instruments and Other Financial Instrument Cash Collateral | The following table presents information about the cash collateral posted by the Company in respect of its derivative and other financial instruments, which is included in the line item “deposits, net” in the accompanying consolidated balance sheets, for the dates indicated: March 31, 2020 December 31, 2019 Cash collateral posted for: Interest rate swaps (cash initial margin) $ 4,569 $ 37,122 Unsettled MBS trades and TBA commitments, net 28,439 1 Total cash collateral posted, net $ 33,008 $ 37,123 |
TBA Commitments | |
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | |
Schedule of Derivative Instruments | The following table presents information about the Company’s TBA commitments as of the date indicated: March 31, 2020 Notional Amount: Purchase (Sale) Commitment Contractual Forward Price Market Price Fair Value 2.5% 30-year MBS purchase commitments $ 450,000 $ 451,422 $ 465,961 $ 14,539 2.5% 30-year MBS sale commitments (450,000 ) (455,930 ) (465,961 ) (10,031 ) 3.0% 30-year MBS purchase commitments 100,000 102,477 104,875 2,398 3.0% 30-year MBS sale commitments (100,000 ) (103,133 ) (104,875 ) (1,742 ) Total TBA commitments, net $ — $ (5,164 ) $ — $ 5,164 As of December 31, 2019, the Company had no outstanding TBA commitments. |
Interest Rate Swap | |
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | |
Schedule of Derivative Instruments | The following table presents information about the Company’s interest rate swap agreements that were in effect as of March 31, 2020: Weighted-average: Notional Amount Fixed Pay Rate Variable Receive Rate Net Receive (Pay) Rate Remaining Life (Years) Fair Value Years to maturity: Less than 3 years $ 500,000 1.78 % 1.65 % (0.13 )% 1.0 $ (49 ) 3 to less than 5 years 100,000 1.52 % 0.77 % (0.75 )% 4.7 20 Total / weighted-average $ 600,000 1.73 % 1.50 % (0.23 )% 1.6 $ (29 ) The following table presents information about the Company’s interest rate swap agreements that were in effect as of December 31, 2019: Weighted-average: Notional Amount Fixed Pay Rate Variable Receive Rate Net Receive (Pay) Rate Remaining Life (Years) Fair Value Years to maturity: Less than 3 years $ 2,050,000 1.77 % 1.92 % 0.15 % 1.6 $ 83 3 to less than 7 years 510,000 1.61 % 1.92 % 0.31 % 6.0 439 7 to less than 10 years 400,000 2.24 % 1.91 % (0.33 )% 9.5 715 10 or more years 25,000 2.96 % 1.90 % (1.06 )% 28.2 172 Total / weighted-average $ 2,985,000 1.81 % 1.92 % 0.11 % 3.6 $ 1,409 |
Offsetting of Financial Asset_2
Offsetting of Financial Assets and Liabilities (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Offsetting [Abstract] | |
Offsetting of Financial Assets and Liabilities | The following tables present information, as of the dates indicated, about the Company’s derivative instruments, short-term borrowing arrangements, and associated collateral, including those subject to master netting (or similar) arrangements: As of March 31, 2020 Gross Amount Recognized Amount Offset in the Consolidated Balance Sheets Net Amount Presented in the Consolidated Balance Sheets Gross Amount Not Offset in the Consolidated Balance Sheets Net Amount Financial Instruments (1) Cash Collateral (2) Assets: Derivative instruments: Interest rate swaps $ 26 $ — $ 26 $ (4 ) $ — $ 22 TBA commitments 16,937 — 16,937 (11,773 ) — 5,164 Total derivative instruments 16,963 — 16,963 (11,777 ) — 5,186 Total assets $ 16,963 $ — $ 16,963 $ (11,777 ) $ — $ 5,186 Liabilities: Derivative instruments: Interest rate swaps $ 55 $ — $ 55 $ (4 ) $ (51 ) $ — TBA commitments 11,773 — 11,773 (11,773 ) — — Total derivative instruments 11,828 — 11,828 (11,777 ) (51 ) — Repurchase agreements 2,036,466 — 2,036,466 (2,036,466 ) — — Total liabilities $ 2,048,294 $ — $ 2,048,294 $ (2,048,243 ) $ (51 ) $ — As of December 31, 2019 Gross Amount Recognized Amount Offset in the Consolidated Balance Sheets Net Amount Presented in the Consolidated Balance Sheets Gross Amount Not Offset in the Consolidated Balance Sheets Net Amount Financial Instruments (1) Cash Collateral (2) Assets: Derivative instruments: Interest rate swaps $ 1,417 $ — $ 1,417 $ — $ — $ 1,417 Total derivative instruments 1,417 — 1,417 — — 1,417 Total assets $ 1,417 $ — $ 1,417 $ — $ — $ 1,417 Liabilities: Derivative instruments: Interest rate swaps $ 8 $ — $ 8 $ (8 ) $ — $ — Total derivative instruments 8 — 8 (8 ) — — Repurchase agreements 3,581,237 — 3,581,237 (3,581,237 ) — — Total liabilities $ 3,581,245 $ — $ 3,581,245 $ (3,581,245 ) $ — $ — (1) Does not include the fair value amount of financial instrument collateral pledged in respect of repurchase agreements that exceeds the associated liability presented in the consolidated balance sheets. (2) Does not include the amount of cash collateral pledged in respect of derivative instruments that exceeds the associated derivative liability presented in the consolidated balance sheets. |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Fair Value Disclosures [Abstract] | |
Summary of Significant Inputs to Fair Value Measurement of Non-agency RMBS | The following table presents the significant inputs to the fair value measurement of the Company’s non-agency RMBS as of March 31, 2020: March 31, 2020 Annualized default rate 7.3 % Loss-given-default 40.0 % Discount rate 10.1 % |
Financial Instruments Measured at Fair Value on a Recurring Basis | The following tables set forth financial instruments measured at fair value by level within the fair value hierarchy as of March 31, 2020 and December 31, 2019. Assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. March 31, 2020 Total Level 1 Level 2 Level 3 Agency MBS $ 645,001 $ — $ 645,001 $ — Non-agency MBS 32,623 — 23,457 9,166 Mortgage loans 44,614 — — 44,614 Derivative assets 16,963 — 16,963 — Derivative liabilities (11,828 ) — (11,828 ) — Other assets 5,812 — — 5,812 Total $ 733,185 $ — $ 673,593 $ 59,592 December 31, 2019 Total Level 1 Level 2 Level 3 Agency MBS $ 3,768,496 $ — $ 3,768,496 $ — Non-agency MBS 33,501 — 33,478 23 Mortgage loans 45,000 — — 45,000 Derivative assets 1,417 — 1,417 — Derivative liabilities (8 ) — (8 ) — Other assets 6,375 — — 6,375 Total $ 3,854,781 $ — $ 3,803,383 $ 51,398 |
Change in Fair Value of Level 3 Investments that are Measured at Fair Value on Recurring Basis | The table below sets forth an attribution of the change in the fair value of the Company’s Level 3 investments that are measured at fair value on a recurring basis for the periods indicated: Three Months Ended March 31, 2020 2019 Beginning balance $ 51,398 $ 6,139 Included in investment gain (loss), net (3,609 ) (156 ) Purchases 11,995 — Sales — — Payments, net (410 ) (80 ) Accretion of discount 218 1 Ending balance $ 59,592 $ 5,904 Net unrealized gains (losses) included in earnings for the period for Level 3 assets still held at the reporting date $ (3,609 ) $ (156 ) |
Earnings (Loss) Per Share (Tabl
Earnings (Loss) Per Share (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Earnings Per Share [Abstract] | |
Computations of Basic and Diluted Earnings (Loss) Per Share | The following tables present the computations of basic and diluted earnings (loss) per share for the periods indicated: Three Months Ended March 31, (Shares in thousands) 2020 2019 Basic weighted-average common shares outstanding 36,711 33,053 Performance share units, unvested restricted stock units, and unvested restricted stock — 86 Diluted weighted-average common shares outstanding 36,711 33,139 Net (loss) income (attributable) available to common stock $ (94,944 ) $ 17,316 Basic (loss) earnings per common share $ (2.59 ) $ 0.52 Diluted (loss) earnings per common share $ (2.59 ) $ 0.52 |
Stockholders' Equity (Tables)
Stockholders' Equity (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Schedule of Dividends Payable | For the quarter ended March 31, 2020, the Board of Directors determined that the Company would not declare a dividend on its common stock. The Board of Directors approved and the Company declared and paid the following dividends on its common stock for 2019: Quarter Ended Dividend Amount Declaration Date Record Date Pay Date December 31 $ 0.225 December 13 December 31 February 3, 2020 September 30 0.225 September 17 September 30 October 31 June 30 0.225 June 24 July 5 July 31 March 31 0.375 March 18 March 29 April 30 |
Series B Preferred Equity Distribution Agreement | |
Issuances of Stock under Equity Distribution Agreements | During the three months ended March 31, 2020, there were no issuances of preferred stock under the Series B preferred equity distribution agreement. The following table provides information about the issuances of preferred stock under the Series B preferred equity distribution agreements for the period indicated: Series B Preferred Stock Issuances Year Ended December 31, 2019 Shares issued 3,444 Weighted average public offering price $ 22.39 Net proceeds (1) $ 76 (1) Net of selling commissions and expenses. |
Organization and Basis of Pre_2
Organization and Basis of Presentation - Additional Information (Details) | 3 Months Ended |
Mar. 31, 2020 | |
Organization Consolidation And Presentation Of Financial Statements [Abstract] | |
Required annual distribution of taxable income | 90.00% |
Intended annual distribution of taxable income | 100.00% |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies - Additional Information (Details) | Mar. 31, 2020 | Dec. 31, 2019 |
Accounting Policies [Abstract] | ||
Cash Equivalents Percentage Held in Us Government Backed Securities | 99.00% | 97.00% |
Investments in Agency MBS - Add
Investments in Agency MBS - Additional Information (Details) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Agency MBS | ||
Fair Value of MBS | $ 645,001 | $ 3,768,496 |
Investments in Agency MBS - A_2
Investments in Agency MBS - Additional Information About Gains and Losses Recognized with Respect to Investments in Agency MBS (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Net gains (losses) recognized in earnings for: | ||
Total | $ 3,094 | $ 69,168 |
Agency MBS | ||
Net gains (losses) recognized in earnings for: | ||
MBS still held at period end | 12,127 | 62,109 |
MBS sold during the period | 11,391 | 7,056 |
Total | $ 23,518 | $ 69,165 |
Investments in Non-Agency MBS -
Investments in Non-Agency MBS - Additional Information (Details) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Non-Agency MBS | ||
Fair Value of MBS | $ 32,623 | $ 33,501 |
Investments in Non-Agency MBS_2
Investments in Non-Agency MBS - Additional Information About Gains and Losses Recognized with Respect to Investments in Non-Agency MBS (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Net gains (losses) recognized in earnings for: | ||
Total | $ 3,094 | $ 69,168 |
Non-Agency MBS | ||
Net gains (losses) recognized in earnings for: | ||
MBS still held at period end | (15,618) | 3 |
MBS sold during the period | (4,420) | |
Total | $ (20,038) | $ 3 |
Investments in Mortgage Loans -
Investments in Mortgage Loans - Additional Information (Details) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended |
Mar. 31, 2020 | Dec. 31, 2019 | |
Schedule Of Investments [Line Items] | ||
Purchases of mortgage loans | $ 45,000 | |
Mortgage Loan Rate | LIBOR plus 4.25 | |
Mortgage loan maturity date | Dec. 31, 2021 | |
Fair value of investments in mortgage loans | $ 44,614 | $ 45,000 |
Minimum | ||
Schedule Of Investments [Line Items] | ||
Mortgage loan floor rate | 6.25% |
Borrowings - Additional Informa
Borrowings - Additional Information (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2020 | Dec. 31, 2019 | |
Debt Instrument [Line Items] | ||
Mortgage Loan Rate | LIBOR plus 4.25 | |
Mortgage loan maturity date | Dec. 31, 2021 | |
Long-term unsecured debt | $ 74,383 | $ 74,328 |
Unamortized debt issuance costs | $ 917 | $ 972 |
Agency MBS | ||
Debt Instrument [Line Items] | ||
Mortgage Loan Rate | LIBOR plus 2.00% | |
Mortgage loan maturity date | Feb. 9, 2021 | |
Agency MBS | One-Month LIBOR | ||
Debt Instrument [Line Items] | ||
Mortgage loan floor rate | 2.00% | |
Agency MBS | Floor Interest Rate | ||
Debt Instrument [Line Items] | ||
Mortgage loan floor rate | 3.00% | |
Minimum | ||
Debt Instrument [Line Items] | ||
Mortgage loan floor rate | 6.25% | |
Minimum | Agency MBS | ||
Debt Instrument [Line Items] | ||
MBS repurchase agreement contract duration | 30 days | |
Maximum | Agency MBS | ||
Debt Instrument [Line Items] | ||
MBS repurchase agreement contract duration | 60 days | |
Mortgage loan maturity date extension option | 364 days |
Borrowings - Outstanding Repurc
Borrowings - Outstanding Repurchase Agreement Borrowings (Details) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2020 | Dec. 31, 2019 | ||
Repurchase Agreement Counterparty [Line Items] | |||
Repurchase agreements outstanding | $ 2,036,466 | $ 3,581,237 | |
Mortgage investments collateral, at fair value | 2,180,008 | 3,772,146 | |
Net amount | [1] | $ 143,542 | $ 190,909 |
Weighted-average rate | 0.98% | 2.11% | |
Weighted-average term to maturity (in days) | 19 days | 23 days | |
Agency MBS repurchase financing | |||
Repurchase Agreement Counterparty [Line Items] | |||
Repurchase agreements outstanding | $ 1,977,095 | $ 3,560,139 | |
Mortgage investments collateral, at fair value | [2] | 2,094,164 | 3,741,399 |
Net amount | [1] | $ 117,069 | $ 181,260 |
Weighted-average rate | 0.92% | 2.10% | |
Weighted-average term to maturity (in days) | 15 days | 23 days | |
Non-agency MBS repurchase financing | |||
Repurchase Agreement Counterparty [Line Items] | |||
Repurchase agreements outstanding | $ 27,871 | $ 21,098 | |
Mortgage investments collateral, at fair value | [3] | 41,230 | 30,747 |
Net amount | [1] | $ 13,359 | $ 9,649 |
Weighted-average rate | 3.13% | 3.11% | |
Weighted-average term to maturity (in days) | 5 days | 8 days | |
Mortgage loans repurchase financing | |||
Repurchase Agreement Counterparty [Line Items] | |||
Repurchase agreements outstanding | $ 31,500 | ||
Mortgage investments collateral, at fair value | 44,614 | ||
Net amount | [1] | $ 13,114 | |
Weighted-average rate | 3.00% | ||
Weighted-average term to maturity (in days) | 315 days | ||
[1] | Net amount represents the value of collateral in excess of corresponding repurchase obligation. The amount of collateral at-risk is limited to the outstanding repurchase obligation and not the entire collateral balance. | ||
[2] | As of March 31, 2020 and December 31, 2019, includes $1,455,136 and $71,284, respectively, at sale price of unsettled agency MBS sale commitments which are included in the line item “sold securities receivable” in the accompanying consolidated balance sheets. | ||
[3] | As of March 31, 2020, includes $32,607 and $8,623 at fair value of non-agency and agency MBS collateral, respectively. As of December 31, 2019, includes $30,747 at fair value of non-agency MBS collateral. |
Borrowings - Outstanding Repu_2
Borrowings - Outstanding Repurchase Agreement Borrowings (Parenthetical) (Details) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Repurchase Agreement Counterparty [Line Items] | ||
Sold securities receivable | $ 1,479,396 | $ 71,199 |
Pledged as Collateral for Repurchase Agreements | ||
Repurchase Agreement Counterparty [Line Items] | ||
Sold securities receivable | 1,455,136 | 71,284 |
Agency MBS repurchase financing | ||
Repurchase Agreement Counterparty [Line Items] | ||
MBS collateral, at fair value | 8,623 | |
Non-agency MBS repurchase financing | ||
Repurchase Agreement Counterparty [Line Items] | ||
MBS collateral, at fair value | $ 32,607 | $ 30,747 |
Borrowings - Information Regard
Borrowings - Information Regarding Outstanding Repurchase Agreement Borrowings During the Period (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Debt Disclosure [Abstract] | ||
Weighted-average outstanding balance | $ 3,162,340 | $ 3,680,429 |
Weighted-average rate | 1.83% | 2.68% |
Borrowings - Long-term Unsecure
Borrowings - Long-term Unsecured Debt Instruments (Details) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended |
Mar. 31, 2020 | Dec. 31, 2019 | |
Senior Notes Due 2025 | ||
Debt Instrument [Line Items] | ||
Outstanding Principal | $ 35,300 | $ 35,300 |
Annual Interest Rate | 6.75% | 6.75% |
Interest Payment Frequency | Quarterly | Quarterly |
Weighted-Average Interest Rate | 6.75% | 6.75% |
Maturity | Mar. 15, 2025 | Mar. 15, 2025 |
Senior Notes Due 2023 | ||
Debt Instrument [Line Items] | ||
Outstanding Principal | $ 25,000 | $ 25,000 |
Annual Interest Rate | 6.625% | 6.625% |
Interest Payment Frequency | Quarterly | Quarterly |
Weighted-Average Interest Rate | 6.625% | 6.625% |
Maturity | May 1, 2023 | May 1, 2023 |
Trust Preferred Debt | ||
Debt Instrument [Line Items] | ||
Outstanding Principal | $ 15,000 | $ 15,000 |
Interest Payment Frequency | Quarterly | Quarterly |
Weighted-Average Interest Rate | 4.58% | 4.74% |
Annual Interest Rate | LIBOR+ 2.25 - 3.00 % | LIBOR+ 2.25 - 3.00 % |
Trust Preferred Debt | Minimum | ||
Debt Instrument [Line Items] | ||
Maturity | 2033 | 2033 |
Trust Preferred Debt | Maximum | ||
Debt Instrument [Line Items] | ||
Maturity | 2035 | 2035 |
Derivative Instruments - Fair V
Derivative Instruments - Fair Value of Derivative Instruments (Details) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Derivative Assets | $ 16,963 | $ 1,417 |
Derivative Liabilities | (11,828) | (8) |
Interest Rate Swap | ||
Derivative Assets | 26 | 1,417 |
Derivative Liabilities | (55) | (8) |
TBA Commitments | ||
Derivative Assets | 16,937 | 0 |
Derivative Liabilities | $ (11,773) | $ 0 |
Derivative Instruments - Intere
Derivative Instruments - Interest Rate Swap Agreements (Details) - Interest Rate Swap - USD ($) | 3 Months Ended | 12 Months Ended | ||
Mar. 31, 2020 | Dec. 31, 2019 | Mar. 31, 2019 | Dec. 31, 2018 | |
Notional Amount | $ 600,000,000 | $ 2,985,000,000 | $ 2,850,000,000 | $ 3,100,000,000 |
Weighted-average: Fixed Pay Rate | 1.73% | 1.81% | ||
Weighted-average: Variable Receive Rate | 1.50% | 1.92% | ||
Weighted-average: Net Receive (Pay) Rate | (0.23%) | 0.11% | ||
Weighted-average: Remaining Life (in years) | 1 year 7 months 6 days | 3 years 7 months 6 days | ||
Fair Value, Asset and (Liability) | $ (29,000) | $ 1,409,000 | ||
Less Than Three Years Maturity | ||||
Notional Amount | $ 500,000,000 | $ 2,050,000,000 | ||
Weighted-average: Fixed Pay Rate | 1.78% | 1.77% | ||
Weighted-average: Variable Receive Rate | 1.65% | 1.92% | ||
Weighted-average: Net Receive (Pay) Rate | (0.13%) | 0.15% | ||
Weighted-average: Remaining Life (in years) | 1 year | 1 year 7 months 6 days | ||
Fair Value, Asset and (Liability) | $ (49,000) | $ 83,000 | ||
Three To Less Than Five Years Maturity | ||||
Notional Amount | $ 100,000,000 | |||
Weighted-average: Fixed Pay Rate | 1.52% | |||
Weighted-average: Variable Receive Rate | 0.77% | |||
Weighted-average: Net Receive (Pay) Rate | (0.75%) | |||
Weighted-average: Remaining Life (in years) | 4 years 8 months 12 days | |||
Fair Value, Asset and (Liability) | $ 20,000 | |||
Three To Less Than Seven Years Maturity | ||||
Notional Amount | $ 510,000,000 | |||
Weighted-average: Fixed Pay Rate | 1.61% | |||
Weighted-average: Variable Receive Rate | 1.92% | |||
Weighted-average: Net Receive (Pay) Rate | 0.31% | |||
Weighted-average: Remaining Life (in years) | 6 years | |||
Fair Value, Asset and (Liability) | $ 439,000 | |||
Seven to Less Than Ten Years Maturity | ||||
Notional Amount | $ 400,000,000 | |||
Weighted-average: Fixed Pay Rate | 2.24% | |||
Weighted-average: Variable Receive Rate | 1.91% | |||
Weighted-average: Net Receive (Pay) Rate | (0.33%) | |||
Weighted-average: Remaining Life (in years) | 9 years 6 months | |||
Fair Value, Asset and (Liability) | $ 715,000 | |||
Ten or More Years Maturity | ||||
Notional Amount | $ 25,000,000 | |||
Weighted-average: Fixed Pay Rate | 2.96% | |||
Weighted-average: Variable Receive Rate | 1.90% | |||
Weighted-average: Net Receive (Pay) Rate | (1.06%) | |||
Weighted-average: Remaining Life (in years) | 28 years 2 months 12 days | |||
Fair Value, Asset and (Liability) | $ 172,000 |
Derivative Instruments - Additi
Derivative Instruments - Additional Information (Details) - USD ($) | Mar. 31, 2020 | Dec. 31, 2019 |
U.S. Treasury Note Futures | ||
Derivative [Line Items] | ||
Notional Amount | $ 0 | $ 0 |
Forward-Settling TBA Commitments | ||
Derivative [Line Items] | ||
Fair value amount pledged | $ 1,506,000 |
Derivative Instruments - TBA Co
Derivative Instruments - TBA Commitments (Details) - USD ($) | Mar. 31, 2020 | Dec. 31, 2019 |
Fair Value, Asset | $ 16,963,000 | $ 1,417,000 |
Fair Value, Liability | (11,828,000) | (8,000) |
TBA Commitments | ||
Notional Amount: Purchase Commitment | 0 | |
Contractual Forward Price | (5,164,000) | |
Market Price | 0 | |
Fair Value, Asset | 16,937,000 | 0 |
Fair Value, Liability | (11,773,000) | $ 0 |
Fair Value | 5,164,000 | |
TBA Commitments | Two Point Five Percent Thirty Year Mortgage Backed Securities Purchase (Sale) Commitments, Purchase | ||
Notional Amount: Purchase Commitment | 450,000,000 | |
Contractual Forward Price | 451,422,000 | |
Market Price | 465,961,000 | |
Fair Value, Asset | 14,539,000 | |
TBA Commitments | Two Point Five Percent Thirty Year Mortgage Backed Securities Purchase Sale Commitments Sale | ||
Notional Amount: Purchase Commitment | 450,000,000 | |
Contractual Forward Price | (455,930,000) | |
Market Price | (465,961,000) | |
Fair Value, Liability | (10,031,000) | |
TBA Commitments | Three Point Zero Percent Thirty Year Mortgage Backed Securities Purchase (Sale) Commitments, Purchase | ||
Notional Amount: Purchase Commitment | 100,000,000 | |
Contractual Forward Price | 102,477,000 | |
Market Price | 104,875,000 | |
Fair Value, Asset | 2,398,000 | |
TBA Commitments | Three Point Zero Percent Thirty Year Mortgage Backed Securities Purchase (Sale) Commitments, Sale | ||
Notional Amount: Purchase Commitment | 100,000,000 | |
Contractual Forward Price | (103,133,000) | |
Market Price | (104,875,000) | |
Fair Value, Liability | $ (1,742,000) |
Derivative Instruments - Deriva
Derivative Instruments - Derivative Gains and Losses Recognized Within the Periods (Details) - USD ($) $ in Thousands | 3 Months Ended | ||
Mar. 31, 2020 | Mar. 31, 2019 | ||
Interest rate derivative (losses) gains, net | $ (106,458) | $ (64,270) | |
Other derivatives | (1,040) | 0 | |
Total derivative losses, net | (102,600) | (55,205) | |
Interest Rate Swap (Losses) Gains, Net | |||
Interest rate derivative (losses) gains, net | (103,387) | (57,566) | |
Interest Rate Swaps Net Interest Income | |||
Interest rate derivative (losses) gains, net | [1] | 592 | 4,747 |
Interest Rate Swaps Unrealized Losses, Net | |||
Interest rate derivative (losses) gains, net | 5,945 | (63,491) | |
Interest Rate Swaps (Losses) Gains Realized Upon Early Termination, Net | |||
Interest rate derivative (losses) gains, net | (109,924) | 1,178 | |
TBA Dollar Roll Income | |||
Gains (losses) on commitments | [2] | 105 | 1,420 |
Other Gains (Losses) on TBA Commitments, Net | |||
Gains (losses) on commitments | 4,793 | 7,645 | |
Gains (Losses) on TBA Commitments, Net | |||
Gains (losses) on commitments | 4,898 | 9,065 | |
U.S. Treasury Note Futures, Net | |||
Interest rate derivative (losses) gains, net | $ (3,071) | $ (6,704) | |
[1] | Represents the periodic net interest settlement incurred during the period (often referred to as “net interest carry”). Also includes “price alignment interest” income earned or expense incurred on cumulative variation margin paid or received, respectively, associated with centrally cleared interest rate swap agreements. | ||
[2] | Represents the price discount of forward-settling TBA purchases relative to a contemporaneously executed “spot” TBA sale, which economically equates to net interest income that is earned ratably over the period beginning on the settlement date of the sale and ending on the settlement date of the forward-settling purchase. |
Derivative Instruments - Volume
Derivative Instruments - Volume of Activity, in terms of Notional Amount, Related to Derivative Instruments (Details) - USD ($) | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Interest Rate Swap | ||
Derivative [Line Items] | ||
Beginning of Period | $ 2,985,000,000 | $ 3,100,000,000 |
Additions | 0 | 400,000,000 |
Scheduled Settlements | (100,000,000) | 0 |
Early Terminations | (2,285,000,000) | (650,000,000) |
End of Period | 600,000,000 | 2,850,000,000 |
2-year U.S. Treasury Note Futures | ||
Derivative [Line Items] | ||
Beginning of Period | 0 | |
Additions | 1,150,000,000 | |
Scheduled Settlements | 0 | |
Early Terminations | (1,150,000,000) | |
End of Period | 0 | |
10-year U.S. Treasury Note Futures | ||
Derivative [Line Items] | ||
Beginning of Period | 0 | 320,000,000 |
Additions | 765,000,000 | 440,000,000 |
Scheduled Settlements | 0 | (390,000,000) |
Early Terminations | (765,000,000) | (155,000,000) |
End of Period | 0 | 215,000,000 |
TBA Purchase (sale) Commitments, Net | ||
Derivative [Line Items] | ||
Beginning of Period | 0 | 0 |
Additions | 100,000,000 | 2,150,000,000 |
Scheduled Settlements | (100,000,000) | (1,250,000,000) |
Early Terminations | 0 | 0 |
End of Period | 0 | $ 900,000,000 |
Put Options on S&P 500 ETF | ||
Derivative [Line Items] | ||
Beginning of Period | 0 | |
Additions | 1,850,000 | |
Scheduled Settlements | (1,850,000) | |
Early Terminations | 0 | |
End of Period | $ 0 |
Derivative Instruments - Cash C
Derivative Instruments - Cash Collateral Posted in Respect of Derivative and Other Financial Instruments (Details) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Cash collateral posted, net | $ 33,008 | $ 37,123 |
Interest Rate Swap | ||
Cash collateral posted, net | 4,569 | 37,122 |
Unsettled MBS Trades and TBA Commitments, Net | ||
Cash collateral posted, net | $ 28,439 | $ 1 |
Offsetting of Financial Asset_3
Offsetting of Financial Assets and Liabilities - Derivative Instruments and Short-term Borrowing Arrangements, including those Subject to Master Netting or Similar Arrangements (Details) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 | |
Derivative instruments: | |||
Derivative Asset, Gross Amount Recognized | $ 16,963 | $ 1,417 | |
Derivative Asset, Amount Offset | 0 | 0 | |
Derivative Asset, Net Amount | 16,963 | 1,417 | |
Derivative Asset, Financial Instruments | [1] | (11,777) | 0 |
Derivative Asset, Cash Collateral | [2] | 0 | 0 |
Derivative Asset, Net amount Total | 5,186 | 1,417 | |
Derivative instruments: | |||
Derivative Liabilities, Gross Amount Recognized | 11,828 | 8 | |
Derivative Liabilities, Amount Offset | 0 | 0 | |
Derivative Liabilities, Net Amount | 11,828 | 8 | |
Derivative Liabilities, Financial Instruments | [1] | (11,777) | (8) |
Derivative Liabilities, Cash Collateral | [2] | (51) | 0 |
Derivative Liabilities, Net amount Total | 0 | 0 | |
Derivative Financial Instruments, Liabilities | |||
Derivative instruments: | |||
Derivative Liabilities, Gross Amount Recognized | 2,048,294 | 3,581,245 | |
Derivative Liabilities, Amount Offset | 0 | 0 | |
Derivative Liabilities, Net Amount | 2,048,294 | 3,581,245 | |
Derivative Liabilities, Financial Instruments | [1] | (2,048,243) | (3,581,245) |
Derivative Liabilities, Cash Collateral | [2] | (51) | 0 |
Derivative Liabilities, Net amount Total | 0 | 0 | |
Derivative Financial Instruments, Assets | |||
Derivative instruments: | |||
Derivative Asset, Gross Amount Recognized | 16,963 | 1,417 | |
Derivative Asset, Amount Offset | 0 | 0 | |
Derivative Asset, Net Amount | 16,963 | 1,417 | |
Derivative Asset, Financial Instruments | [1] | (11,777) | 0 |
Derivative Asset, Cash Collateral | [2] | 0 | 0 |
Derivative Asset, Net amount Total | 5,186 | 1,417 | |
Repurchase Agreements | |||
Derivative instruments: | |||
Derivative Liabilities, Gross Amount Recognized | 2,036,466 | 3,581,237 | |
Derivative Liabilities, Amount Offset | 0 | 0 | |
Derivative Liabilities, Net Amount | 2,036,466 | 3,581,237 | |
Derivative Liabilities, Financial Instruments | [1] | (2,036,466) | (3,581,237) |
Derivative Liabilities, Cash Collateral | [2] | 0 | 0 |
Derivative Liabilities, Net amount Total | 0 | 0 | |
Interest Rate Swap | |||
Derivative instruments: | |||
Derivative Asset, Gross Amount Recognized | 26 | 1,417 | |
Derivative Asset, Amount Offset | 0 | 0 | |
Derivative Asset, Net Amount | 26 | 1,417 | |
Derivative Asset, Financial Instruments | [1] | (4) | 0 |
Derivative Asset, Cash Collateral | [2] | 0 | 0 |
Derivative Asset, Net amount Total | 22 | 1,417 | |
Derivative instruments: | |||
Derivative Liabilities, Gross Amount Recognized | 55 | 8 | |
Derivative Liabilities, Amount Offset | 0 | 0 | |
Derivative Liabilities, Net Amount | 55 | 8 | |
Derivative Liabilities, Financial Instruments | [1] | (4) | (8) |
Derivative Liabilities, Cash Collateral | [2] | (51) | 0 |
Derivative Liabilities, Net amount Total | 0 | 0 | |
TBA Commitments | |||
Derivative instruments: | |||
Derivative Asset, Gross Amount Recognized | 16,937 | ||
Derivative Asset, Amount Offset | 0 | ||
Derivative Asset, Net Amount | 16,937 | 0 | |
Derivative Asset, Financial Instruments | [1] | (11,773) | |
Derivative Asset, Cash Collateral | [2] | 0 | |
Derivative Asset, Net amount Total | 5,164 | ||
Derivative instruments: | |||
Derivative Liabilities, Gross Amount Recognized | 11,773 | ||
Derivative Liabilities, Amount Offset | 0 | ||
Derivative Liabilities, Net Amount | 11,773 | $ 0 | |
Derivative Liabilities, Financial Instruments | [1] | (11,773) | |
Derivative Liabilities, Cash Collateral | [2] | 0 | |
Derivative Liabilities, Net amount Total | $ 0 | ||
[1] | Does not include the fair value amount of financial instrument collateral pledged in respect of repurchase agreements that exceeds the associated liability presented in the consolidated balance sheets. | ||
[2] | Does not include the amount of cash collateral pledged in respect of derivative instruments that exceeds the associated derivative liability presented in the consolidated balance sheets. |
Fair Value Measurements - Summa
Fair Value Measurements - Summary of Significant Inputs to Fair Value Measurement of Non-agency RMBS (Details) - Non-Agency RMBS - Fair Value, Inputs, Level 3 | Mar. 31, 2020 |
Annualized Default Rate | |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | |
Significant inputs to fair value measurement | 0.073 |
Loss-Given-Default | |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | |
Significant inputs to fair value measurement | 0.400 |
Discount Rate | |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | |
Significant inputs to fair value measurement | 0.101 |
Fair Value Measurements - Addit
Fair Value Measurements - Additional Information (Details) $ in Thousands | 3 Months Ended | |
Mar. 31, 2020USD ($) | Dec. 31, 2019USD ($) | |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Long-term unsecured debt, carrying value | $ 74,383 | $ 74,328 |
Long-term unsecured debt, Fair Value | 54,766 | 70,429 |
Private Equity Funds | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Investment in equity securities and investment funds measured at fair value | $ 5,812 | $ 6,375 |
Fair Value, Inputs, Level 3 | Private Equity Funds | Stock Price to Net Asset Multiple | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Fair value discount rate | 0.67 | 0.95 |
Fair Value, Inputs, Level 3 | Private Equity Funds | Discount Factor for Lack of Marketability and Control | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Fair value discount rate | 0.09 | 0.09 |
Fair Value, Inputs, Level 3 | Private Equity Funds | Cost of Equity Discount Rate | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Fair value discount rate | 0.12 | 0.12 |
Fair Value, Inputs, Level 3 | RMBS | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] | ||
Estimated remaining life period | 1 year 9 months | |
Fair value discount rate | 0.069 |
Fair Value Measurements - Finan
Fair Value Measurements - Financial Instruments Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Mortgage loans, at fair value | $ 44,614 | $ 45,000 |
Derivative assets, at fair value | 16,963 | 1,417 |
Derivative Liabilities | (11,828) | (8) |
Fair Value, Measurements, Recurring | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Mortgage loans, at fair value | 44,614 | 45,000 |
Derivative assets, at fair value | 16,963 | 1,417 |
Derivative Liabilities | (11,828) | (8) |
Other assets | 5,812 | 6,375 |
Total | 733,185 | 3,854,781 |
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 1 | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Mortgage loans, at fair value | 0 | 0 |
Derivative assets, at fair value | 0 | 0 |
Derivative Liabilities | 0 | 0 |
Other assets | 0 | 0 |
Total | 0 | 0 |
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 2 | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Mortgage loans, at fair value | 0 | 0 |
Derivative assets, at fair value | 16,963 | 1,417 |
Derivative Liabilities | (11,828) | (8) |
Other assets | 0 | 0 |
Total | 673,593 | 3,803,383 |
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 3 | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Mortgage loans, at fair value | 44,614 | 45,000 |
Derivative assets, at fair value | 0 | 0 |
Derivative Liabilities | 0 | 0 |
Other assets | 5,812 | 6,375 |
Total | 59,592 | 51,398 |
Fair Value, Measurements, Recurring | Agency MBS | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Trading securities | 645,001 | 3,768,496 |
Fair Value, Measurements, Recurring | Agency MBS | Fair Value, Inputs, Level 1 | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Trading securities | 0 | 0 |
Fair Value, Measurements, Recurring | Agency MBS | Fair Value, Inputs, Level 2 | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Trading securities | 645,001 | 3,768,496 |
Fair Value, Measurements, Recurring | Agency MBS | Fair Value, Inputs, Level 3 | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Trading securities | 0 | 0 |
Fair Value, Measurements, Recurring | Non-Agency MBS | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Trading securities | 32,623 | 33,501 |
Fair Value, Measurements, Recurring | Non-Agency MBS | Fair Value, Inputs, Level 1 | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Trading securities | 0 | 0 |
Fair Value, Measurements, Recurring | Non-Agency MBS | Fair Value, Inputs, Level 2 | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Trading securities | 23,457 | 33,478 |
Fair Value, Measurements, Recurring | Non-Agency MBS | Fair Value, Inputs, Level 3 | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Trading securities | $ 9,166 | $ 23 |
Fair Value Measurements - Chang
Fair Value Measurements - Change in Fair Value of Level 3 Investments that are Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Fair Value Disclosures [Abstract] | ||
Beginning balance | $ 51,398 | $ 6,139 |
Included in investment gain (loss), net | (3,609) | (156) |
Purchases | 11,995 | |
Payments, net | (410) | (80) |
Accretion of discount | 218 | 1 |
Ending balance | 59,592 | 5,904 |
Net unrealized gains (losses) included in earnings for the period for Level 3 assets still held at the reporting date | $ (3,609) | $ (156) |
Income Taxes - Additional Infor
Income Taxes - Additional Information (Details) - USD ($) $ in Thousands | Aug. 21, 2019 | May 29, 2018 | Mar. 31, 2020 | Dec. 31, 2019 |
Income Tax Disclosure [Line Items] | ||||
Intended annual distribution of taxable income | 100.00% | |||
Required annual distribution of taxable income | 90.00% | |||
Estimated net operating loss carryforwards | $ 14,588 | |||
Net operating loss carryforwards, expiration year | 2028 | |||
Capital loss carryforwards expiration remainder of fiscal year | $ 77,685 | |||
Capital loss carryforwards expiration in year 2021 | 66,862 | |||
Capital loss carryforwards expiration in year 2022 | 3,763 | |||
Capital loss carryforwards expiration in year 2023 | $ 110,323 | |||
Excess AMT credit carryforwards refundable rate | 50.00% | |||
AMT credit carryforward | $ 4,566 | $ 4,566 | ||
Income tax examination, description | BPOL tax for the 2017 year remains subject to examination by Arlington County, although the county has previously informally indicated that it did not intend to pursue assessments for that year at such time. | |||
Tax Year 2018 | Arlington County, Virginia | ||||
Income Tax Disclosure [Line Items] | ||||
Tax assessment received for business, professional and occupation license tax | $ 488 | $ 9,380 | ||
Tax Year 2019 | Fairfax County [Member] | ||||
Income Tax Disclosure [Line Items] | ||||
Tax assessment received for business, professional and occupation license tax | 54 | |||
Tax Year 2019 | Arlington County, Virginia | ||||
Income Tax Disclosure [Line Items] | ||||
Revised tax assessment received for business, professional and occupation license tax | $ 471 | |||
Partial refund received for business, professional and occupation license tax | 118 | |||
Tax Year 2018 and 2019 | Arlington County, Virginia | Other General and Administrative Expense | ||||
Income Tax Disclosure [Line Items] | ||||
BPOL tax expense | $ 892 | |||
Tax Year 2017 | Arlington County, Virginia | ||||
Income Tax Disclosure [Line Items] | ||||
Income tax remain subject to examination year | 2017 | |||
Capital Loss Carryforward | ||||
Income Tax Disclosure [Line Items] | ||||
Tax Credit Carryforward, Amount | $ 258,633 |
Earnings (Loss) Per Share - Com
Earnings (Loss) Per Share - Computations of Basic and Diluted Earnings (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Earnings Per Share [Abstract] | ||
Basic weighted-average common shares outstanding | 36,711 | 33,053 |
Performance share units, unvested restricted stock units, and unvested restricted stock | 86 | |
Diluted weighted-average common shares outstanding | 36,711 | 33,139 |
Net (loss) income (attributable) available to common stock | $ (94,944) | $ 17,316 |
Basic (loss) earnings per common share | $ (2.59) | $ 0.52 |
Diluted (loss) earnings per common share | $ (2.59) | $ 0.52 |
Earnings (Loss) Per Share - Add
Earnings (Loss) Per Share - Additional Information (Details) | 3 Months Ended |
Mar. 31, 2020shares | |
Restricted Stock, Restricted Stock Units and Performance Shares | |
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | |
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 106 |
Stockholders' Equity - Addition
Stockholders' Equity - Additional Information (Details) $ / shares in Units, $ in Thousands | Mar. 12, 2019USD ($)$ / sharesshares | Feb. 22, 2019USD ($)$ / sharesshares | Jun. 01, 2009 | Mar. 31, 2020$ / sharesshares | Dec. 31, 2019$ / sharesshares | Sep. 30, 2019$ / shares | Jun. 30, 2019$ / shares | Mar. 31, 2019$ / sharesshares | Dec. 31, 2019$ / sharesshares | Mar. 21, 2019shares | Aug. 10, 2018shares | May 16, 2017shares | Feb. 22, 2017shares |
Share based Compensation Arrangement by Share based Payment Award [Line Items] | |||||||||||||
Dividend Amount (in dollars per share) | $ / shares | $ 0.225 | $ 0.225 | $ 0.225 | $ 0.375 | |||||||||
Declaration Date | Dec. 13, 2019 | Sep. 17, 2019 | Jun. 24, 2019 | Mar. 18, 2019 | |||||||||
Pay Date | Feb. 3, 2020 | Oct. 31, 2019 | Jul. 31, 2019 | Apr. 30, 2019 | |||||||||
Shareholder Rights Plan | |||||||||||||
Share based Compensation Arrangement by Share based Payment Award [Line Items] | |||||||||||||
Rights plan, amended term of agreement | 3 years | ||||||||||||
Common Stock | Common Equity Distribution Agreements | |||||||||||||
Share based Compensation Arrangement by Share based Payment Award [Line Items] | |||||||||||||
Issuance of stock (in shares) | 0 | 0 | |||||||||||
Common Class A | |||||||||||||
Share based Compensation Arrangement by Share based Payment Award [Line Items] | |||||||||||||
Common stock, shares authorized (in shares) | 450,000,000 | 450,000,000 | 450,000,000 | ||||||||||
Common stock, par value (in dollars per share) | $ / shares | $ 0.01 | $ 0.01 | $ 0.01 | ||||||||||
Common Stock Voting Rights Per Share Owned | 1 | ||||||||||||
Common stock, shares outstanding (in shares) | 36,815,761 | 36,755,387 | 36,755,387 | ||||||||||
Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased | 1,951,305 | ||||||||||||
Common Class A | Maximum | |||||||||||||
Share based Compensation Arrangement by Share based Payment Award [Line Items] | |||||||||||||
Stock Repurchase Program, Number of Shares Authorized to be Repurchased | 2,000,000 | ||||||||||||
Common Class A | Minimum | Shareholder Rights Plan | |||||||||||||
Share based Compensation Arrangement by Share based Payment Award [Line Items] | |||||||||||||
Percentage of beneficial ownership of common stock | 4.90% | ||||||||||||
Common Class A | Common Stock | |||||||||||||
Share based Compensation Arrangement by Share based Payment Award [Line Items] | |||||||||||||
Issuance of stock (in shares) | 6,000,000 | 6,000,000 | |||||||||||
Public Offering Price Per Share | $ / shares | $ 8.16 | ||||||||||||
Net proceeds underwriting discounts and commissions and expenses | $ | $ 48,827 | ||||||||||||
Repurchase of Class A common stock (in shares) | 0 | 0 | |||||||||||
Common Class A | Common Stock | Common Equity Distribution Agreements | |||||||||||||
Share based Compensation Arrangement by Share based Payment Award [Line Items] | |||||||||||||
Number of shares offer and sell | 11,302,160 | ||||||||||||
Common Class A | Common Stock | Maximum | Common Equity Distribution Agreements | |||||||||||||
Share based Compensation Arrangement by Share based Payment Award [Line Items] | |||||||||||||
Number of shares offer and sell | 6,000,000 | ||||||||||||
Common Class A | Common Stock | Maximum | Equity Distribution Agreements | |||||||||||||
Share based Compensation Arrangement by Share based Payment Award [Line Items] | |||||||||||||
Number of shares offer and sell | 12,597,423 | ||||||||||||
Common Class B | |||||||||||||
Share based Compensation Arrangement by Share based Payment Award [Line Items] | |||||||||||||
Common stock, shares authorized (in shares) | 100,000,000 | ||||||||||||
Common stock, par value (in dollars per share) | $ / shares | $ 0.01 | ||||||||||||
Common Stock Voting Rights Per Share Owned | 3 | ||||||||||||
Common stock, shares outstanding (in shares) | 0 | 0 | 0 | ||||||||||
7.00% Series B Cumulative Perpetual Redeemable Preferred Stock | |||||||||||||
Share based Compensation Arrangement by Share based Payment Award [Line Items] | |||||||||||||
Preferred stock, shares authorized (in shares) | 2,000,000 | ||||||||||||
Preferred stock, par value (in dollars per share) | $ / shares | $ 0.01 | ||||||||||||
Series C Preferred Stock | |||||||||||||
Share based Compensation Arrangement by Share based Payment Award [Line Items] | |||||||||||||
Public Offering Price Per Share | $ / shares | $ 25 | ||||||||||||
Net proceeds underwriting discounts and commissions and expenses | $ | $ 28,944 | ||||||||||||
Preferred stock, shares authorized (in shares) | 2,500,000 | ||||||||||||
Preferred stock, par value (in dollars per share) | $ / shares | $ 0.01 | $ 0.01 | $ 0.01 | ||||||||||
Preferred stock, dividend rate percentage | 8.25% | ||||||||||||
Preferred stock voting rights per share owned | 0 | ||||||||||||
Preferred stock, liquidation preference per share | $ / shares | $ 25 | ||||||||||||
Preferred stock, redeemable price per share | $ / shares | $ 25 | ||||||||||||
Preferred stock, dividend payment terms | Dividends will be payable quarterly in arrears on the 30th day of March, June, September and December of each year, when and as declared, beginning on June 30, 2019. | ||||||||||||
Preferred stock, annual dividend rate per share | $ / shares | $ 2.0625 | ||||||||||||
Preferred stock, rate conversion date | Mar. 30, 2024 | ||||||||||||
Series C Preferred Stock | LIBOR | |||||||||||||
Share based Compensation Arrangement by Share based Payment Award [Line Items] | |||||||||||||
Preferred stock, variable dividend spread rate | 5.664% | ||||||||||||
Series C Preferred Stock | Preferred Stock | |||||||||||||
Share based Compensation Arrangement by Share based Payment Award [Line Items] | |||||||||||||
Issuance of stock (in shares) | 1,200,000 | 1,200,000 | |||||||||||
Undesignated Preferred Stock | |||||||||||||
Share based Compensation Arrangement by Share based Payment Award [Line Items] | |||||||||||||
Preferred stock, shares authorized (in shares) | 20,400,000 | ||||||||||||
Series A Preferred Stock | |||||||||||||
Share based Compensation Arrangement by Share based Payment Award [Line Items] | |||||||||||||
Preferred stock, shares authorized (in shares) | 100,000 | ||||||||||||
Preferred stock shares unissued | 100,000 | ||||||||||||
Series B Preferred Stock | |||||||||||||
Share based Compensation Arrangement by Share based Payment Award [Line Items] | |||||||||||||
Preferred stock, par value (in dollars per share) | $ / shares | $ 0.01 | $ 0.01 | $ 0.01 | ||||||||||
Preferred stock, dividend rate percentage | 7.00% | ||||||||||||
Preferred stock voting rights per share owned | 0 | ||||||||||||
Preferred stock, liquidation preference per share | $ / shares | $ 25 | ||||||||||||
Preferred stock, redeemable price per share | $ / shares | $ 25 | ||||||||||||
Preferred stock, redemption date | May 12, 2022 | ||||||||||||
Preferred stock, dividend payment terms | Dividends are payable quarterly in arrears on the 30th day of March, June, September and December of each year, when and as declared. | ||||||||||||
Preferred stock, annual dividend rate per share | $ / shares | $ 1.75 | ||||||||||||
Series B Preferred Stock | Preferred Stock | |||||||||||||
Share based Compensation Arrangement by Share based Payment Award [Line Items] | |||||||||||||
Issuance of stock (in shares) | 2,035 | ||||||||||||
Series B Preferred Stock | Preferred Stock | Series B Preferred Equity Distribution Agreement | |||||||||||||
Share based Compensation Arrangement by Share based Payment Award [Line Items] | |||||||||||||
Issuance of stock (in shares) | 0 | 3,444 | |||||||||||
Number of Shares Offer and Sell | 1,645,961 | ||||||||||||
Series B Preferred Stock | Preferred Stock | Maximum | |||||||||||||
Share based Compensation Arrangement by Share based Payment Award [Line Items] | |||||||||||||
Number of Shares Offer and Sell | 1,865,000 | ||||||||||||
Series B Preferred Stock | Preferred Stock | Maximum | Series B Preferred Equity Distribution Agreement | |||||||||||||
Share based Compensation Arrangement by Share based Payment Award [Line Items] | |||||||||||||
Number of Shares Offer and Sell | 1,647,370 |
Stockholders' Equity - Dividend
Stockholders' Equity - Dividends Declared and Paid (Details) - $ / shares | 3 Months Ended | |||
Dec. 31, 2019 | Sep. 30, 2019 | Jun. 30, 2019 | Mar. 31, 2019 | |
Equity [Abstract] | ||||
Dividend Amount (in dollars per share) | $ 0.225 | $ 0.225 | $ 0.225 | $ 0.375 |
Declaration Date | Dec. 13, 2019 | Sep. 17, 2019 | Jun. 24, 2019 | Mar. 18, 2019 |
Record Date | Dec. 31, 2019 | Sep. 30, 2019 | Jul. 5, 2019 | Mar. 29, 2019 |
Pay Date | Feb. 3, 2020 | Oct. 31, 2019 | Jul. 31, 2019 | Apr. 30, 2019 |
Stockholders' Equity - Issuance
Stockholders' Equity - Issuances of Preferred Stock under Equity Distribution Agreements (Details) - Series B Preferred Stock - Preferred Stock - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 12 Months Ended | ||
Mar. 31, 2020 | Mar. 31, 2019 | Dec. 31, 2019 | ||
Class Of Stock [Line Items] | ||||
Shares issued | 2,035 | |||
Series B Preferred Equity Distribution Agreement | ||||
Class Of Stock [Line Items] | ||||
Shares issued | 0 | 3,444 | ||
Weighted average public offering price | $ 22.39 | |||
Net proceeds | [1] | $ 76 | ||
[1] | Net of selling commissions and expenses |